CN1059905C - 雷怕霉素羟基酯,它们的制备方法及其药用组合物 - Google Patents
雷怕霉素羟基酯,它们的制备方法及其药用组合物 Download PDFInfo
- Publication number
- CN1059905C CN1059905C CN95193325A CN95193325A CN1059905C CN 1059905 C CN1059905 C CN 1059905C CN 95193325 A CN95193325 A CN 95193325A CN 95193325 A CN95193325 A CN 95193325A CN 1059905 C CN1059905 C CN 1059905C
- Authority
- CN
- China
- Prior art keywords
- compound
- alkyl
- carbon atom
- acceptable salt
- pharmacy acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title claims description 18
- 238000000034 method Methods 0.000 title claims description 17
- 238000002360 preparation method Methods 0.000 title claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title claims 17
- 229960002930 sirolimus Drugs 0.000 title claims 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 95
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 37
- 239000001257 hydrogen Substances 0.000 claims abstract description 31
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 31
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 18
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 12
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 11
- 125000003884 phenylalkyl group Chemical group 0.000 claims abstract description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 58
- -1 silyl ethyl Chemical group 0.000 claims description 25
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 9
- 125000006239 protecting group Chemical group 0.000 claims description 9
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 206010052779 Transplant rejections Diseases 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 238000005917 acylation reaction Methods 0.000 claims description 5
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 4
- WJZIPMQUKSTHLV-UHFFFAOYSA-N 2-ethyldecanoic acid Chemical compound CCCCCCCCC(CC)C(O)=O WJZIPMQUKSTHLV-UHFFFAOYSA-N 0.000 claims description 4
- 241000233866 Fungi Species 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 235000019260 propionic acid Nutrition 0.000 claims description 4
- 208000037803 restenosis Diseases 0.000 claims description 4
- OZPFVBLDYBXHAF-UHFFFAOYSA-N 2,2-dimethyl-1,3-dioxolane-4-carboxylic acid Chemical group CC1(C)OCC(C(O)=O)O1 OZPFVBLDYBXHAF-UHFFFAOYSA-N 0.000 claims description 3
- 206010061217 Infestation Diseases 0.000 claims description 3
- AYDQIZKZTQHYIY-UHFFFAOYSA-N OC(=O)C1(C)CC(C(O)=O)=CC=C1 Chemical compound OC(=O)C1(C)CC(C(O)=O)=CC=C1 AYDQIZKZTQHYIY-UHFFFAOYSA-N 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- DBXBTMSZEOQQDU-UHFFFAOYSA-N 3-hydroxyisobutyric acid Chemical compound OCC(C)C(O)=O DBXBTMSZEOQQDU-UHFFFAOYSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
- 230000010933 acylation Effects 0.000 claims 2
- RBNPOMFGQQGHHO-UHFFFAOYSA-N glyceric acid Chemical group OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 claims 2
- ULMZOZMSDIOZAF-UHFFFAOYSA-N 3-hydroxy-2-(hydroxymethyl)propanoic acid Chemical group OCC(CO)C(O)=O ULMZOZMSDIOZAF-UHFFFAOYSA-N 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract description 3
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 abstract description 3
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 abstract description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract description 3
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 230000001028 anti-proliverative effect Effects 0.000 abstract description 2
- 239000002246 antineoplastic agent Substances 0.000 abstract description 2
- 125000000532 dioxanyl group Chemical group 0.000 abstract 4
- 125000004849 alkoxymethyl group Chemical group 0.000 abstract 1
- 230000000843 anti-fungal effect Effects 0.000 abstract 1
- 229940121375 antifungal agent Drugs 0.000 abstract 1
- 125000004276 dioxalanyl group Chemical group 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 78
- 150000001721 carbon Chemical group 0.000 description 41
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 32
- 239000000203 mixture Substances 0.000 description 32
- 238000010998 test method Methods 0.000 description 29
- 239000007787 solid Substances 0.000 description 26
- 239000000243 solution Substances 0.000 description 25
- 239000012634 fragment Substances 0.000 description 23
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 235000019439 ethyl acetate Nutrition 0.000 description 16
- 238000005160 1H NMR spectroscopy Methods 0.000 description 14
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 14
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- 239000007788 liquid Substances 0.000 description 13
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 12
- 238000001035 drying Methods 0.000 description 12
- 238000003818 flash chromatography Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 206010061218 Inflammation Diseases 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 208000009386 Experimental Arthritis Diseases 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 8
- 206010020718 hyperplasia Diseases 0.000 description 8
- 239000012266 salt solution Substances 0.000 description 8
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 239000012299 nitrogen atmosphere Substances 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 238000003828 vacuum filtration Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 229910001873 dinitrogen Inorganic materials 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 150000008065 acid anhydrides Chemical class 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- OZGSEIVTQLXWRO-UHFFFAOYSA-N 2,4,6-trichlorobenzoyl chloride Chemical compound ClC(=O)C1=C(Cl)C=C(Cl)C=C1Cl OZGSEIVTQLXWRO-UHFFFAOYSA-N 0.000 description 4
- 229930105110 Cyclosporin A Natural products 0.000 description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 4
- 230000001857 anti-mycotic effect Effects 0.000 description 4
- 229960001265 ciclosporin Drugs 0.000 description 4
- 238000010520 demethylation reaction Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002543 antimycotic Substances 0.000 description 3
- 210000000621 bronchi Anatomy 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000002769 thiazolinyl group Chemical group 0.000 description 3
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 150000001263 acyl chlorides Chemical class 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 201000006966 adult T-cell leukemia Diseases 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 230000017858 demethylation Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- CXUAEBDTJFKMBV-UHFFFAOYSA-N 1-(chloromethyl)-2,3,4,5,6-pentamethylbenzene Chemical compound CC1=C(C)C(C)=C(CCl)C(C)=C1C CXUAEBDTJFKMBV-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920001273 Polyhydroxy acid Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010039361 Sacroiliitis Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000187391 Streptomyces hygroscopicus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001032 anti-candidal effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- FNIATMYXUPOJRW-UHFFFAOYSA-N cyclohexylidene Chemical group [C]1CCCCC1 FNIATMYXUPOJRW-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 150000005826 halohydrocarbons Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000065 osmolyte Effects 0.000 description 1
- 230000000661 pacemaking effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- QQVIHTHCMHWDBS-UHFFFAOYSA-N perisophthalic acid Natural products OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000005671 trienes Chemical class 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Domestic Plumbing Installations (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
结构式(Ⅰ)的化合物或其药学上可接受的盐:
其中:
R1和R2每个独立地是氢或-CO(CR3R4)b(CR5R6)dCR7R8R9;R3和R4每个独立地是氢,烷基,链烯基,炔基,三氟甲基或-F;R5和R6独立地是氢,烷基,链烯基,炔基,-(CR3R4)fOR10,-CF3,-F,或-CO2R11,或者R5和R6可以一起形成X或环烷环,它们可以被-(CR3R4)fOR10单,双或三非强制性地取代;R7是氢,烷基,链烯基,炔基,-(CR3R4)fOR10,-CF3,-F,或-CO2R11;R8和R9独立地是氢,烷基,链烯基,炔基,-(CR3R4)fOR10,-CF3,-F,或-CO2R11,或者R8和R9可以一起形成X或环烷环,它们可以被-(CR3R4)fOR10单,双或三非强制性地取代;R10是氢,烷基,链烯基,炔基,三(烷基)甲硅烷基,三(烷基)甲硅烷基乙基,三苯甲基,苄基,烷氧甲基,三(烷基)甲硅烷基乙氧甲基,氯乙基或四氢吡喃基,R11是氢,烷基,链烯基,炔基或苯基烷基;X是5-(2,2-二烷基)[1,3]二烷基,5-(2-螺-环烷基)[1,3]二烷基,4-(2,2-二烷基)[1,3]二烷基,4-(2-螺-环烷基)[1,3]二烷基,4-(2,2-二烷基)[1,3]二氧杂环戊烷基,或4-(2-螺-环烷基)[1,3]二氧杂环戊烷基;b=0-6;d=0-6;以及f=0-6,其条件是R1和R2两者不同时是氢,另一条件是R1或者R2至少含一个-(CR3R4)fOR10,X,或-(CR3R4)fOR10取代的3-8个碳原子的环烷基。它们可以用作免疫抑制,抗炎,抗真菌,抗增生和抗肿瘤剂。
Description
发明的背景
本发明涉及雷怕霉素羟基酯,使用它们诱发免疫抑制的方法以及治疗移植排斥,对宿主的移植物疾病(graft vs.host disease),自身免疫疾病,炎症,成人T-细胞白血病/淋巴瘤,实体瘤,真菌感染及血管过度增生疾病。
雷怕霉素是由链霉菌属Streptomyces hygroscopicus生产的大环三烯类抗生素,发现它有抗真菌活性,尤其是在体外及体内抗白色念珠菌的活性(C.Vezina等人,抗生素杂志(J.Antibiot.),28,721(1975);S.N.Sehgal等人,抗生素杂志,28,727(1975);H.A.Baker等人,抗生素杂志,31,539(1978);美国专利3,929,992;和美国专利3,993,749)。
雷怕霉素单独(美国专利4,885,171)或者和溶链菌结合(美国专利4,401,653)具有抗肿瘤活性;R.Martel等人〔加拿大生理学与药理学杂志(Can.J.Physiol.Pharmacol.)55,48(1977)〕公开了雷怕霉素在试验过敏性脑脊髓炎模型,一种多发性硬化症模型及在佐剂性关节炎(adjuvant arthritis)模型,一种类风湿性关节炎模型中是有效的,并且能有效地抑制类IgE抗体的形成。
雷怕霉素的免疫抑制效果已经公开在FASEB 3,3411(1989)中,环孢菌素A和FK-506,另一种大环分子作为免疫抑制剂也是有效的,因此可用于预防移植排斥〔FASEB 3,3411(1989);FASEB 3,5256(1989);R.Y.Calne等人,Lancet 1183(1978);美国专利5,100,899〕。
雷怕霉素也用于预防或治疗系统性红斑狼疮;〔美国专利5,078,999〕;肺炎〔美国专利5,080,899〕,胰岛素依赖型糖尿病〔炎性疾病研究协会第五次国际会议(Fifth Int.Conf.Inflamm.Res.Assoc.)121(摘要),(1990)〕,平滑肌细胞增生及血管损伤引起的内膜变厚〔Morris,R.J.心肺移植(Heart Lung Transplant)11(pt.2);197(1992)〕,成年人T细胞白血病/淋巴瘤〔欧洲专利申请525,960A1〕和眼炎〔欧洲专利申请532,862A1〕。
雷怕霉素的单或双酰基衍生物(在28和43位酯化)已显示出可用于抗真菌(美国专利4,316,885)以及用于制成雷怕霉素的水溶性氨酰基前药(美国专利4,650,803)。最近,关于雷怕霉素的常规编号变化了,因此,按照C.A命名法,上述酯处在31-和42-位。
发明的详细描述:
本发明提供了一种雷怕霉素衍生物或其药学上可接受的盐,它可用作免疫抑制,抗炎,抗真菌,抗增生和抗肿瘤剂,其结构如下:其中:R1和R2每个独立地是氢或-CO(CR3R4)b(CR5R6)dCR7R8R9;R3和R4每个独立地是氢,1-6个碳原子的烷基,2-7个碳原子的链
烯基,2-7个碳原子的炔基,三氟甲基或-F;R5和R6每个独立地是氢,1-6个碳原子的烷基,2-7个碳原子的链
烯基,2-7个碳原子的炔基,-(CR3R4)fOR10,-CF3,-F或-CO2R11,
或者R5和R6可以一起形成X或3-8个碳原子的环烷环,它们可
以被-(CR3R4)fOR10单,双或三非强制性地取代;R7是氢,1-6个碳原子的烷基,2-7个碳原子的链烯基,2-7个
碳原子的炔基,-(CR3R4)fOR10,-CF3,-F或-CO2R11;R8和R9每个独立地是氢,1-6个碳原子的烷基,2-7个碳原子的链
烯基,2-7个碳原子的炔基,-(CR3R4)fOR10,-CF3,-F,或-CO2R11,
或者R8和R9可以一起形成X或3-8个碳原子的环烷环,它们可
以被-(CR3R4)fOR10单,双或三非强制性地取代;R10是氢,1-6个碳原子的烷基,2-7个碳原子的链烯基,2-7个
碳原子的炔基,三(1-6个碳原子的烷基)甲硅烷基,三(1-6
个碳原子的烷基)甲硅烷基乙基,三苯甲基,苄基,2-7个碳原
子的烷氧甲基,三(1-6个碳原子的烷基)甲硅烷基乙氧甲基,
氯乙基,或四氢吡喃基;R11是氢,1-6个碳原子的烷基,2-7个碳原子的链烯基,2-7个
碳原子的炔基,或苯基烷基(7-10个碳原子);X是5-(2,2-二(1-6个碳原子的烷基))[1,3]二噁烷基,5-
(2-螺(3-8个碳原子的环烷基))[1,3]二噁烷基,4-(2,2
-二(1-6个碳原子的烷基))[1,3]-二噁烷基,4-(2-螺
(3-8个碳原子的环烷基))[1,3]二噁烷基,4-(2,2-二(1
-6个碳原子的烷基))[1,3]二氧杂环戊烷基,或4-(2-螺(3
-8个碳原子的环烷基))[1,3]二氧杂环戊烷基;b是0-6;d是0-6;及f是O-6其条件是R1和R2两者不同时是氢,另一条件是R1或者R2至少含一个-(CR3R4)f-OR10,X,或是被-(CR3R4)f-OR10取代的3-8个碳原子的环烷基。
药学上可接受的盐是从无机阳离子如钠,钾等得到的,或者是从有机碱如每个烷基是1-6个碳原子的单-,双-或三烷基胺以及每个烷基是1-6个碳原子的单-,双-或三-羟基烷基胺得到的。
术语1-6个碳原子的烷基,2-7个碳原子的链烯基和2-7个碳原子的炔基包括直链的及支链的碳链。因为本发明化合物可含一个以上的-(CR3R4)fOR10基团,R3,R4,f和R10可以相同或不同;同样,当其它一般取代基在同一结构中重复的时候,它们也可以相同或不同。
对于其中R1含R8和R9一起形成X的化合物,当X是5-(2,2-二(1-6个碳原子的烷基))[1,3]二噁烷基,X的烷基含1个碳原子,且d=0时,R1有以下结构:
对于含X的化合物,优选的化合物包括其中X的烷基,如果存在的话,是甲基,以及X的环烷基,如果存在的话,是环己基的化合物。
当R10不是氢,烷基,链烯基或炔基时,是指R10是可作为醇保护基的基团,因之,这种基团是未羟基化化合物的中间体并且本身是有生物学活性的。R10包括三(1-6个碳原子的烷基)甲硅烷基,三(1-6个碳原子的烷基)甲硅烷基乙基,三苯甲基,苄基,2-7个碳原子的烷氧甲基,三(1-6个碳原子的烷基)甲硅烷基乙氧甲基,氯乙基和四氢吡喃基。其它的醇保护基是本领域技术人员公知的,并且可以看作是本发明的一部分。
在本发明的化合物中,优选其中R2是氢的化合物;R2是氢,而且b=0及d=0的化合物;R2是氢,b=0,d=0,而且R8和R9每个独立地是氢,烷基或是-(CR3R4)fOR10,或者一起形成X的化合物。
在42或31,42位有酯基-CO(CR3R4)b(CR5R6)dCR7R8R9的本发明化合物可以通过用保护的羟基及多羟基酸,已被活化的烷氧基或多烷氧基羧酸使雷怕霉素酰化来制备,随后如果需要的话,除去醇保护基。某些羧酸酯活化的方法是本领域公知的,但优选的方法是使用碳化二亚胺,混合酸酐或酰氯。例如,适当取代的羧酸能以混合酸酐活化,用如2,4,6-三氯苯甲酰氯的酰基活化。雷怕霉素在温和的碱性条件下用混合酸酐处理可提供所需的化合物。另外,酰化反应可用1-(3-二甲氨基丙基)-3-乙基碳化二亚胺盐酸盐和二甲氨基吡啶实现。42-和31,42-酯的混合物可用色谱法分离。
因之,本发明提供了制备本发明的雷怕霉素化合物的方法,具体地说,本发明提供了制备雷怕霉素羟基酯,包括上述定义的式I化合物的方法,该方法包括:a)用酰化剂酰化雷怕霉素或其官能衍生物或其类似物;或b)连续用两种酰化剂酰化雷怕霉素,或其官能衍生物或其类似物;所述酰化剂选自下式(II)或其活性衍生物:
HO-CO(CR3R4)b(CR5R6)dCR7R8R9 (II)其中R3-R9,b和d的定义如上述,条件是,假如需要用适当的保护基保护雷怕霉素或其官能衍生物的42位时,将游离羟基保护起来,如果需要,反应后再除去任何保护基。
反应可在偶联剂存在下进行,如适当取代的碳化二亚胺偶联剂。本发明上述化合物也能用式II酸的活性衍生物如酸酐,混合酸酐或酰卤如酰氯通过酰化反应制备。
本发明的31-酯-42-羟基化合物可以通过用保护基如叔丁基二甲基甲硅烷基保护雷怕霉素42位醇,随后用上述方法酯化31位而制备。制备雷怕霉素42-甲硅烷基醚记载于美国专利Bl5,120,842中,本文结合其内容作为参考。除去保护基得到31位酯化的化合物。在叔丁基二甲基甲硅烷基保护基情况下,脱保护可在温和的酸性条件下,如乙酸/水/THF中完成。脱保护方法记载于美国专利5,118,678的实施例15中,本文结合其内容作为参考。
完成31位酯化和42位脱保护之后,42位可用与和31位醇反应不同的酰化剂进行酯化,因而得到在31位和42位有不同酯的化合物。另外上述制备的42位酯化的化合物,能和不同的酰化剂反应,得到在31位和42位有不同酯的化合物。
本发明也包括其它雷怕霉素的类似的羟基酯,例如但不限于29-去甲氧雷怕霉素〔美国专利4,375,464,C.A命名法是32-去甲氧雷怕霉素〕;其中1,3,和/或5位的双键是被还原的雷怕霉素衍生物〔美国专利5,023,262〕;29-脱甲基雷怕霉素〔美国专利5,093,339,C.A命名法是32-脱甲基雷怕霉素〕;7,29-双脱甲基雷怕霉素〔美国专利5,093,338,C.A命名法是7,32-双脱甲基雷怕霉素〕以及15-羟基雷怕霉素〔美国专利5,102,876〕,上述美国专利公开本文结合在本文中作为参考。
本发明代表化合物的免疫抑制活性用体外标准的药理学试验方法测定抑制淋巴细胞的增生(LAF)和两种体内标准的药理学试验方法评价。点状皮肤移植试验方法测定试验化合物的免疫抑制活性以及试验化合物抑制和治疗移植排斥的能力。佐剂性关节炎标准药理学试验方法测定试验化合物抑制免疫调节的炎症的能力。佐剂性关节炎试验方法对于类风湿性关节炎是一种标准的药理学试验方法,这些标准药理学试验方法的程序如下述。
Comitogen诱发的胸腺细胞增生方法(LAF)用作体外测定代表性化合物的免疫抑制效果的方法。简要地说,正常BALB/c鼠的胸腺细胞用PHA和IL-1培养72小时,于最后6小时用氚化的胸苷起搏。细胞用及不用各种浓度的雷怕霉素,环孢菌素A或试验化合物培养。收集细胞,测定结合的放射性。和对于未用药物处理的对照组比较计算每分钟百分数的变化,评价淋巴增生的抑制。为了评价每一个化合物,也对雷怕霉素进行评价作为比较,得到各试验化合物及雷怕霉素的IC50值。当作为比较物评价本发明的代表性化合物时,雷怕霉素的IC50范围是0.6-1.5nM。所得结果提供了IC50以及在0.1μm时T细胞增生的百分抑制。本发明的代表性化合物所得结果也作为与雷怕霉素相比的比率表示。正的比率指出免疫抑制活性。大于1的比率说明试验化合物比雷怕霉素能在更大程度上抑制胸腺细胞的增生。比率的计算如下:
在体内试验方法中,测定从雄性BALB/c供者移植到雄性C3H(H-2K)受者的点状移植皮片的存活时间,以评价本发明代表性化合物。采用Billingham R.E.和Medawar P.B.,实验生物学杂志(J.Exp.Biol.)28:385-402(1951)中所述方法。简要地说,供者的点状移植皮片作为同种移植移植到受者的背部,并且以在同一区域的同系移植作为对照,受者用不同浓度的试验化合物腹膜内或口服给药,雷怕霉素用作试验对照,未处理的受者作为排斥对照。每天监视移植物,记录观察结果,直到移植物变干并形成变黑的痂。这天被认为是排斥日。药物处理组的平均移植物存活时间(天数±S.D.)和对照组比较,下表显示出得到的结果。结果以平均存活时间的天数表示。未处理的(对照)点状移植皮片一般在6-7天内被排斥。化合物的试验剂量是4mg/kg。
佐剂性关节炎标准药理学试验方法测定试验化合物预防免疫调节炎症的能力及抑制和治疗类风湿性关节炎的能力。下面简要描述所用的试验方法:一组鼠(雄性近亲繁殖Wistar Lewis鼠)用被试验的化合物预处理(抗原前1小时),然后用Freud’s Complete Adjuvant(FCA)注射在右后爪,以诱发关节炎。对鼠从第0-14天于星期一,星期三,星期五的日程按日共口服给药7个剂量。于第16,23和第30天测量两只后爪。测定第16天与第0天爪体积的差数,得到与对照组比较的百分变化。T细胞调节炎症引起左后爪(未注射的爪)发炎,并记录于上表中(与对照组比较的%变化)。另一方面,非特异性炎症引起右后爪发炎。试验化合物剂量是5mg/kg。结果以未注射的爪在第16天对于对照组百分变化表示。百分变化越是负值,化合物就越有效。雷怕霉素对于对照的变化是-70%--90%,说明雷怕霉素治疗的鼠比对照鼠少70-90%免疫诱发的炎症。
在制备试验的特定化合物的方法之后获得这些标准药理学试验方法得到的结果。
这些标准药理学试验方法的结果说明本发明化合物在体外及体内均有免疫抑制活性。LAF试验方法得到的结果说明对T细胞增生的抑制,因而阐明了本发明化合物的免疫抑制活性。皮肤移植和佐剂性关节炎标准药理学试验方法得到的结果进一步显示本发明化合物作为免疫抑制剂的效用。另外,皮肤移植试验方法得到的结果进一步说明本发明化合物治疗和抑制移植排斥的能力。佐剂性关节炎标准药理学试验方法得到的结果进一步说明本发明化合物治疗和抑制类风湿性关节炎的能力。
基于上述标准药理学试验方法的结果,本发明化合物可用于治疗和抑制移植排斥,如肾,心脏,肝,肺,骨髓,胰腺(胰岛细胞),角膜,小肠和皮肤的异体移植和心脏辨膜的异种移植。治疗和抑制自身免疫疾病如狼疮,类风湿性关节炎,糖尿病,重症肌无力和多发性硬化症,以及炎性疾病如牛皮癣,皮炎,湿疹,皮脂溢,肠发炎,肺炎(包括气喘,慢性阻塞性肺病,肺气肿,急性呼吸困难综合症,支气管炎等)以及眼色素层炎。
根据得到的上述活性概况,本发明化合物也被认为有抗肿瘤,抗真菌和抗增生活性。本发明化合物因此还可用于治疗实体瘤,成人T细胞白血病/淋巴瘤,真菌感染和过度增生的血管病如再狭窄和动脉粥样硬化。当用于再狭窄时,本发明化合物优选用于治疗出现在血管形成术后的再狭窄,当用于此目的时,可将本发明化合物在术前,手术期间或手术后,或上述各种情况结合的方式使用。
当治疗和抑制上述疾病时,本发明化合物可以给哺乳动物经口,非肠道,鼻内,支气管内,透皮,局部,阴道内或直肠使用。
可以期望,本发明化合物用作免疫抑制或抗炎剂时,它们能和一种或几种其它免疫调节剂一起使用。所述其它免疫调节剂包括,但不限于是硫唑嘌呤,皮质甾醇如强的松和甲基强的松龙,环磷酰胺,雷怕霉素,环孢菌素A,FK-506,OKT-3和ATG。将本发明化合物和上述其它药剂结合使用以诱发免疫抑制和治疗炎症,每种药剂仅需要较少的剂量就可达到希望的效果。Stepkowski建立了这种结合治疗的基础,他的研究结果表明在低治疗剂量下结合使用雷怕霉素和环孢菌素A大大延长了心脏同种移植的存活时间〔Transplantation Proc.23:507(1991)〕。
本发明化合物能单独地或和药用载体一起配成制剂用于需要治疗的哺乳动物。药用载体可以是固体或液体。当配制口服药剂时,发现于PHOSAL PG-50(带1,2-丙二醇的磷脂浓缩物A.Nattermann &Cie.GmbH)中的0.01%的吐温80提供了一种可接受的口服配方。
固体载体可包括一种或多种物质,它们可以作为调味剂,润滑剂,增溶剂,悬浮剂,填充剂,滑动剂,压缩助剂,粘合剂或片剂崩解剂,也可以是胶囊化材料。在粉剂中,载体是能和精细分散的活性成份混合的精细分散的固体。在片剂中,活性成份和适当比例的有需要的压缩性能的载体混合,并压缩成需要的形状和大小。粉剂和片剂优选含直到99%的活性成份。合适的固体载体例如包括:磷酸钙,硬脂酸镁,滑石,蔗糖,乳糖,糊精,淀粉,明胶,纤维素,甲基纤维素,羧甲基纤维素钠,聚乙烯吡咯烷,低熔点蜡和离子交换树脂。
液体载体用于制备溶液,悬浮液,乳液,糖浆,酏剂和加压的组合物。活性成份可溶解于或悬浮于药学可接受的液体载体中如水,有机溶剂,两者的混合物或药学上可接受的油或脂肪中。液体载体可以含有其它合适的药学上可接受的添加剂如增溶剂,乳化剂,缓冲剂,防腐剂,甜味剂,调味剂,悬浮剂,增稠剂,着色剂,粘度调节剂,稳定剂或渗透调节剂。对于口服和非肠道给药的液体载体的合适的实例包括水(部分含有上述添加剂如纤维素衍生物,优选羧甲基纤维素钠溶液),醇类(包括单羟基醇和多羟基醇如甘醇)及它们的衍生物,以及油(例如精馏的椰子油和花生油)。对于非肠道给药,载体可以是油的酯如油酸乙酯和十四烷酸异丙酯。无菌液体载体可用于非肠道给药的无菌液体形式的组合物。加压组合物的液体载体可以是卤代烃及其它药学上可接受的推进剂。
无菌溶液或悬浮液的液体药用组合物例如可以用于肌肉内,腹膜内及皮下给药。无菌溶液也可以用于静脉给药。化合物也能以固体或液体组合物的形式口服给药。
本发明化合物能以常规的栓剂形式直肠给药。对于鼻内或支气管内吸入或吹入法给药,本发明化合物可以配制成水的或部分水的溶液,它们能以气雾剂的形式被使用。本发明化合物还可以通过使用含活性化合物和载体的透皮补片进行透皮给药,载体应是对活性化合物隋性的对皮肤无毒并能将全身吸收的药物通过皮肤输送至血流中。载体可以是各种形式如乳膏,软膏,糊剂,凝胶及包藏装置。乳膏和软膏可以是水包油或油包水型的粘性液体或半固体乳液。含有分散于含活性成份的石油或亲水石油中的吸收粉末的糊剂也是可用的。各种包藏装置可以将活性成份释放到血液系统,如半透膜复盖在含有或无载体的活性成份的贮器上,或复盖在含活性成份的基质上,其它包藏装置是文献中已知的。
此外,本发明化合物还可以通过用药学上可接受的赋形剂配制成溶液,乳膏或洗剂使用,其中含0.1-5%,优选2%的活性成份,它们可以用于真菌侵害的部位。
剂量要求随使用的具体组合物,给药方式,病症的严重程度及被治疗的具体对象改变。根据标准药理学试验方法得到的结果,活性化合物的日投药剂量是0.1μg/kg-100mg/kg,优选0.001-25mg/kg,更优选0.01-5mg/kg。治疗一般从少于化合物最佳剂量的较小剂量开始,随后在未治愈情况下增加剂量直到最佳效果。口服,非肠道,鼻内或支气管内给药的精确剂量取决于用药医生根据对每个被治疗患者的经验。药用组合物优选单位剂量形式,例如片剂或胶囊。在此种情况下,组合物被细分成含适当量活性成份的单位剂量;单位剂量形式可以是包装的组合物,例如:包装的粉剂,小瓶,安瓿,预先装好的含液体的注射器或含液体的袋剂。单位剂量形式可以例如是胶囊或片剂本身,或者是各种包装形式的任何上述组合物。
下述实施例阐明本发明代表性化合物的制备方法及生物活性。
实施例1(四氢吡喃-2-基氧基)乙酸雷怕霉素42-酯
于0℃及氮气氛下,将2,4,6-三氯苯甲酰氯(0.55ml,3.51mmol)用注射器加入到乙醇酸THP-醚(0.562g,3.51mmol)和三乙胺(0.49ml,3.51mmol)的THF(10ml)溶液中,室温搅拌混合物4小时,形成白色沉淀,真空过滤除去白色沉淀,用氮气流和温水浴浓缩滤液,残留物溶于10ml苯中,加入雷怕霉素(2.92g,3.19mmol)和DMAP(0.429g,3.51mmol),将混合物于室温搅拌过夜。混合物用EtOAc稀释,用冷的1N HCl水溶液,饱和NaHCO3水溶液及食盐水洗涤,用MgSO4干燥,过滤,浓缩得到油状黄色固体,经快速色谱法提纯(2X 65%EtOAc-己烷),得到标题化合物(1.114g,33%),为白色固体。(-)FAB-MS m/z 1055.5(M-),590.3(S(southern)碎g),463.2(N(northern)碎片)1H NMR(400MHz,d-6 DMSO)δ4.60(m,1H,C(42)H),4.66(m,1H),4.14(s,2H),3.73(m,1H),3.42(m,1H).13C NMR(100.6MHz,d-6 DMSO)δ169.2,97.4,63.5,61.2,29.7,24.8,18.8.
实施例2羟乙酸雷怕霉素42-酯
于0℃将对甲苯磺酸(10mg)加入到实施例1产品(306mg,0.29mmol)于10ml CH3OH中的溶液中,室温搅拌该溶液2小时,用饱和NaHCO3停止反应,水相用3X EtOAc萃取,合并的有机相用食盐水洗涤,用MgSO4干燥,过滤,浓缩得到白色固体,用快速色谱法提纯(2X,EtOAc),得到标题化合物(145mg,51%),为白色固体。(-)FAB-MS m/z 971.3 M-),590(S碎片),379.1(N碎片).1H NMR(400MHz,d-6 DMSO)δ4.60(m,1H,C(42)H),3.98(s,2H).13C NMR(100.6MHz.,d-6 DMSO)δ172.1,59.7.标准药理学试验方法得到的结果:LAF IC50:1.80nMLAF比率:0.83
在佐剂性关节炎实验中对对照组的百分变化为-88%
实施例32,2-二甲基-3-(四氢吡喃-2-基氧基)丙酸雷怕霉素42-酯
于0℃及氮气氛下,往2,2-二甲基-3-羟基丙酸THP-醚(0.319g,1.58mmol)和三乙胺(0.22ml,1.58mmol)于5ml无水THF中的溶液中通过注射器滴加2,4,6-三氯苯甲酰氯(0.25ml,1.58mmol),于室温搅拌混合物4.5小时,真空过滤除去白色沉淀,用氮气流及温水浴浓缩滤液,残留物溶于5ml苯中,加入雷怕霉素(1.31g,1.43mmol)和DMAP(0.193g,1.58mmol),室温搅拌混合物过夜,用EtOAc稀释,用1N HCl水溶液,饱和NaHCO3水溶液,水及食盐水洗涤,MgSO4干燥,过滤并浓缩得到黄色油性固体,用快速色谱法提纯(1X60%EtOAc-己烷,1X 55%EtOAc-己烷),得到标题化合物(0.356g,23%),为白色固体。(-)FAB-MS m/z 1097.7(M-),590.4(S碎片),505.3(N碎片).1H NMR(400MHz,d-6 DMSO)δ4.55(m,1H,C(42)H),4.55(m,1H),3.69(m,1H),3.60(m,2H),3.42(m,1H),1.13(s,3H),1.11(s,3H).13C NMR(100.6MHz,d-6 DMSO)δ175.0,98.0,73.8,60,7,42.6,30.0,24.9,22.0,21.6,18.7.标准药理学试验方法得到的结果:LAF IC50:7.10nMLAF比率:0.34
实施例43-羟基-2,2-二甲基丙酸雷怕霉素42-酯
将对甲苯磺酸(10mg)加入到于0℃下的实施例3产品(250mg,0.23mmol)于10ml CH3OH中的溶液中,室温搅拌该溶液2小时,用饱和NaHCO3溶液停止反应,水相用3X EtOAc萃取,合并的有机相用食用盐水洗涤,用MgSO4干燥,过滤并浓缩得到白色固体。用快速色谱法提纯(2X 75%EtOAc-己烷),得到标题化合物(103mg,45%),为白色固体。(-)FAB-MS m/z 1013.3(M-),590.2(S碎片),421.1(N碎片)1H NMR(400MHz,d-6 DMSO)δ4.48(m,1H,C(42)H),3.39(d,2H),1.06(s,6H).13C NMR(100.6MHz,d-6 DMSO)δ175.5,68.0,44.1,21.7.标准药理学试验方法得到的结果:LAF IC50:0.80nMLAF比率:1.25皮移植物存活时间:10.7±0.5天
实施例5和62,2-二甲基[1,3]二氧杂环戊烷-4-羧酸雷怕霉素42-酯(实施例5)2,2-二甲基[1,3]二氧杂环戊烷-4-羧酸雷怕霉素31,42-双酯(实施例6)
于0℃及氮气氛下,将2,4,6-三氯苯甲酰氯(0.56ml,3.61mmol)通过注射器加入到2,3-二羟基丙酸异亚丙基缩酮(0.527g,3.61mmol)和三乙胺(0.50ml,3.61mmol)于10ml THF中的溶液中,室温搅拌混合物4小时,真空过滤除去白色沉淀,用氮气流和温水浴浓缩滤液,残留物溶于15ml苯中,先加入雷怕霉素(3.00g,3.28mmol),再加入DMAP(0.441g,3.61mmol),室温搅拌混合物过夜,用EtOAc稀释混合物,用冷的1N HCl水溶液,饱和NaHCO3水溶液和食盐水洗涤,用MgSO4干燥,过滤并浓缩得到黄色泡沫状物,用硅胶快速色谱法提纯(梯度洗脱:50-60-75-100%EtOAc-己烷,4X 65%EtOAc-己烷),得到标题化合物。极性较小的31,42-双酯(0.415g)先洗脱下来,极性较大的单酯(0.601g,16%)后洗脱下来,为白色固体。实施例5(-)FAB-MS m/z 1041.4(M-),590.3(S碎片),449.2(N碎片)1H NMR(400MHz,d-6 DMSO)δ4.6(m,1H,C(42)H),4.6(m,1H),4.20(dd,1H),3.96(m,1H),1.36(s,3H),1.30(s,3H).13C NMR(100.6MHz,d-6 DMSO)δ170.5,110.2,73.4,66.6,25.7,25.4.实施例6(-)FAB-MS m/z 1169.6(M-).1H NMR(400MHz,d-6 DMSO)δ5.3(m,1H,C(31)H),4.6(m,1H,C(42)H),4.6(m,2H),4.19(t,1H),4.13(t,1H),3.9(m,2H),1.36(s,3H),1.33(s,3H),1.30(s,3 H),1.28(s,3H).13C NMR(100.6MHz,d-6 DMSO)δ170.5,169.2,110.3,110.2,73.4,66.6,66.5,25.8,25.7,25.4,25.1.标准药理学试验方法得到的结果:实施例5LAF IC50:1.20nMLAF比率:0.74实施例6LAF IC50:1.30nMLAF比率:0.5
实施例72,3-二羟基丙酸雷怕霉素42-酯
实施例5产品(351mg,0.34mmol)在10ml THF和10ml 1N HCl中的溶液于室温下搅拌6小时,混合物用EtOAc稀释,用饱和NaHCO3溶液和食盐水洗涤,用MgSO4干燥,过滤并浓缩成油状物。用快速色谱法提纯(1X EtOAc,1X 10%MeOH-CH2C12,1X 5%MeOH-EtOAc),得到标题化合物(78mg,23%),为白色固体。(-)FAB-MS m/z 1001.2(M-),590.2(S碎片),409.1(N碎片)1H NMR(400MHz,d-6 DMSO)δ4.5(m,1H,C(42)H),3.60(m,1H),3.45(m,2H).标准药理学试验方法得到的结果:LAF IC50:1.4nMLAF比率:0.40
实施例82,2-二甲基[1,3]二噁烷-5-羧酸雷怕霉素42-酯
于0℃及氮气氛下将2,4,6-三氯苯甲酰氯(0.98ml,6.27mmol)通过注射器加到2-(羟甲基)-3-羟基丙酸异亚丙基缩酮(1.000g,6.24mmol)和三乙胺(0.90ml,6.46mmol)于20ml THF中的溶液中,将混合物于室温搅拌4小时,形成白色沉淀,真空过滤除去白色沉淀,用氮气流和温水浴浓缩滤液,残留物溶于20ml苯中,加入雷怕霉素(5.70g,6.24mmol)和DMAP(0.762g,6.24mmol),于室温将混合物搅拌过夜。用EtOAc稀释混合物,用H2O和食盐水洗涤,用MgSO4干燥,过滤并浓缩,得到黄色固体,快速色谱法提纯(75%EtOAc-己烷)得到标题化合物(4.17g,63%),为白色固体。(-)FAB-MS m/z 1055.8(M-),590.5(S碎片),463.4(N碎片)1H NMR(400MHz,d-6 DMSO)δ4.55(m,1H,C(42)H),3.95(m,4H),130(s,6H).13C NMR(100.6MHz,d-6 DMSO)δ170.1,97.4,59.5,24.8,22.5.标准药理学试验方法得到的结果:LAF IC50:0.76nMLAF比率:0.45
实施例93-羟基-2-羟甲基丙酸雷怕霉素42-酯
实施例8产品(3.30g,3.12mmol)于50ml THF和25ml 1N HCl中的溶液于室温搅拌2小时,用饱和NaHCO3溶液稀释,用EtOAc萃取(3X),合并的有机相用饱和NaCl水溶液洗涤,用MgSO4干燥,过滤并浓缩得到黄色泡沫状物。用快速色谱法提纯(1X EtOAc,2X 5%EtOH-EtOAc),得到标题化合物(1.68g,53%),为白色固体。(-)FAB-MS m/z 1015.5(M-),590.3(S碎片),423.3(N碎片)1H NMR(400MHz.d-6DMSO)δ4.6(br s,2H),4.55(m,1H,C(42)H),3.55(m,4H),2.57-2.53(m,1H).13C NMR(100.6MHz,d-6 DMSO)δ172.2,59.3,51.5标准药理学试验方法得到的结果:LAF IC50:0.84nMLAF比率:0.57
实施例102,2,5-三甲基[1,3]二噁烷-5-羧酸雷怕霉素42-酯
于0℃及氮气氛下,往2,2-双(羟甲基)丙酸异亚丙基缩酮(1.041g,5.98mmol)(按照Bruice,美国化学会志(J.Am.Chem.Soc.)89:3568(1967)方法制备)和三乙胺(0.83ml,5.98mmol)于20ml无水THF中的溶液中加入2,4,6-三氯苯甲酰氯(0.93ml,5.98mmol),室温下将所得白色悬浮液搅拌5小时,真空过滤除去沉淀,再用10ml无水THF淋洗烧瓶和滤饼,旋转蒸发浓缩滤液,得到白色固体。残留物溶于20ml无水苯中,加入雷怕霉素(5.47g,5.98mmol)和DMAP(0.731g,5.98mmol),室温搅拌过夜,用EtOAc稀释混合物,用水和饱和NaCl水溶液洗涤,用MgSO4干燥,过滤并蒸发得到黄色油状物。用快速色谱法提纯(5X 60%EtOAc-己烷),得到标题化合物(2.2g,34%),为白色固体。(-)FAB-MS m/z 1069.5(M-),590.3(S碎片),477.2(N碎片).1H NMR(400MHz,d-6 DMSO)δ4.57(m,1H,C(42)H),4.02(d,2H),3.60(d,2H),1.34(s,3H),1.24(s,3H),1.06(s,3H).13C NMR(100.6MHz,d-6 DMSO)δ173.2,99.0,65.0,22.2,18.1.标准药理学试验方法得到的结果:LAF IC50:4.90nMLAF比率:0.41皮移植物存活时间:11.0±1.3天
实施例112,2-双(羟甲基)丙酸雷怕霉素42-酯
实施例10产品(2.8g,2.65mmol)于50ml THF和25ml 1N HCl中的溶液于室温下搅拌4小时,用水稀释混合物,用EtOAc萃取三次。合并的有机相用饱和NaHCO3溶液,饱和NaCl溶液洗涤,用MgSO4干燥,过滤并蒸发得到黄色油状固体物。用快速色谱法提纯(3X EtOAc),得到标题化合物(1.6g,59%)。(-)FAB-MS m/z 1029.6(M-),590.4(S碎片),437.3(N碎片).1H NMR(400MHz,d-6 DMSO)δ4.5(m,1H,C(42)H),3.45(s,4H),1.04(s,3H).13C NMR(100.6MHz,d-6 DMSO)δ174.2,63.7,63.6,49.9,16.8.标准药理学试验方法得到的结果:LAF IC50:0.80和1.80nMLAF比率:1.00和0.44皮移植物存活时间:11.4±1.5和12.0±1.1天佐剂性关节炎对对照组的百分变化:-88%
实施例122,2-二甲基-5-(2-三甲基硅烷基乙氧甲基)[1,3]-二噁烷-5-羧酸雷怕霉素42-酯
于0℃及氮气氛下,将2,4,6-三氯苯甲酰氯(0.14ml,0.86mmol)通过注射器加入到2,2-双(羟甲基)-2-(2-三甲基甲硅烷基乙氧)丙酸异亚丙基缩酮(0.250g,0.86mmol)和三乙胺(0.12ml,0.86mmol)于2ml THF中的溶液中,室温下搅拌混合物4小时,形成白色沉淀,真空过滤除去白色沉淀,用氮气流和温水浴浓缩滤液。残留物溶于2ml苯中,加入雷怕霉素(0.786g,0.86mmol)和DMAP(0.105g,0.86mmol),室温下将混合物搅拌过夜,用EtOAc稀释混合物,用水和食盐水洗涤,用MgSO4干燥,过滤并浓缩得到黄色固体。快速色谱法提纯(梯度洗脱:40-60-80-100%EtOAc-己烷),得到标题化合物(0.559g,54%),为白色固体。(-)FAB-MS m/z 1185.2(M-),590.1(S碎片),593(N碎片).1H NMR(400MHz,d-6 DMSO)δ4.55(m,1H,C(42)H),3.73(m,4H),3.57(s,2H),3.43(t,2H),1.29(s,6H),0.79(t,2H),-0.04(s,9H).13C NMR(100.6MHz,d-6 DMSO)δ171.1,97.7,70.2,68.1,61.3,46.0,24.6,22.1,14.6,-1.3.标准药理学试验方法得到的结果:LAF IC50:7.20nMLAF比率:0.05
实施例13和143-甲基-1,5-二氧杂-螺[5,5]十一烷-3-羧酸雷怕霉素42-酯(实施例13)3-甲基-1,5-二氧杂-螺[5,5]十一烷-3-羧酸雷怕霉素31,42-二酯(实施例14)
于0C及氮气氛下,将2,4,6-三氯苯甲酰氯(0.16ml,1.0mmol)通过注射器加入到2,3-二羟基丙酸亚环己基缩酮(0.214g,1.0mmol)和三乙胺(0.14ml,1.0mmol)于2.5ml THF中的溶液中。室温搅拌混合物4小时,真空过滤除去白色沉淀,用氮气流和温水浴浓缩滤液。残留物溶于3ml苯中,依次加入雷怕霉素(0.457g,0.5mmol)和DMAP(0.061g,0.5mmol),室温搅拌混合物过夜,用EtOAc稀释混合物,用冷的1N HCl水溶液,饱和NaHCO3水溶液和食盐水洗涤,用MgSO4干燥,过滤并浓缩,得到黄色泡沫状物。硅胶快速色谱法提纯(45-50%EtOAc-己烷),得到标题化合物。先洗脱下31,42-二酯(0.168g,26%),后洗脱下的是极性更大的42-单酯(0.301g,52%),分离产品,为白色固体。实施例13(-)FAB-MS m/z 1109.5(M-),590.3(S碎片),517.3(N碎片)1H NMR(400MHz,d-6 DMSO)δ4.55(m,1H,C(42)H),3.61(t,4H),1.04(s,3H).13C NMR(100.6MHz,d-6 DMSO)δ173.3,97.2,64.2.实施例14(-)FAB-MS m/z 1305.6(M-).1H NMR(400MHz,d-6 DMSO)δ5.25(m,1H,C(31)H),4.55(m,1H,C(42)H),3.64-3.54(m,8H),1.05(s,3H),0.97(s,3H).13C NMR(100.6MHz,d-6 DMSO)δ173.2,172.1,97.3,97.2,64.3,64.2,63.9.标准药理学试验方法得到的结果:实施例13LAF IC50:0.6nMLAF比率:2.00实施例14LAF:在0.1μM下抑制T细胞增生43%
Claims (21)
1.下述结构式的化合物或其药学上可接受的盐:其中:R1和R2每个独立地是氢或-CO(CR3R4)b(CR5R6)dCR7R8R9;R3和R4每个独立地是氢或1-6个碳原子的烷基;R5和R6独立地是氢、1-6个碳原子的烷基、-(CR3R4)fOR10、-CF3,或者R5和R6可以一起形成X;R7是氢、1-6个碳原子的烷基、-(CR3R4)fOR10或-CO2R11;R8和R9独立地是氢、1-6个碳原子的烷基、-(CR3R4)fOR10或-CO2R11,或者R8和R9可以一起形成X;R10是氢、1-6个碳原子的烷基、三(1-6个碳原子的烷基)甲硅烷基乙基或四氢吡喃基;R11是氢、1-6个碳原子的烷基、2-7个碳原子的链烯基、2-7个碳原子的炔基或7-10个碳原子的苯基烷基;X是5-(2,2-二(1-6个碳原子的烷基))[1,3]二噁烷基、5-(2-螺(3-8个碳原子的环烷基))[1,3]二噁烷基、4-(2,2-二(1-6个碳原子的烷基))[1,3]二噁烷基、4-(2-螺(3-8个碳原子的环烷基))[1,3]二噁烷基、4-(2,2-二(1-6个碳原子的烷基))[1,3]二氧杂环戊烷基或4-(2-螺(3-8个碳原子的环烷基))[1,3]二氧杂环戊烷基;b=0-6;d=0-6;以及f=0-6,其条件是R1和R2两者不同时是氢,另一条件是R1或者R2至少含一个-(CR3R4)fOR10或X。
2.按照权利要求1的化合物或其药学上可接受的盐,其中R2是氢。
3.按照权利要求1的化合物或其药学上可接受的盐,其中b=0,d=0。
4.按照权利要求3的化合物或其药学上可接受的盐,其中R8和R9每个独立地是氢、烷基或-(CR3R4)fOR10或者一起形成X。
5.按照权利要求1的化合物,它是(四氢吡喃-2-基氧基)乙酸雷帕霉素42-酯或其药学上可接受的盐。
6.按照权利要求1的化合物,它是羟基乙酸雷帕霉素42-酯或其药学上可接受的盐。
7.按照权利要求1的化合物,它是2,2-二甲5-3-(四氢吡喃-2-基氧基)丙酸雷帕霉素42-酯或其药学上可接受的盐。
8.按照权利要求1的化合物,它是3-羟基-2,2-二甲基丙酸雷帕霉素42-酯或其药可接受的盐。
9.按照权利要求1的化合物,它是2,2-二甲基[1,3]二氧杂环戊烷-4-羧酸雷帕霉素42-酯或其药学上可接受的盐。
10.按照权利要求1的化合物,它是2,2-二甲基[1,3]二氧杂环戊烷-4-羧酸31,42-二酯或其药学上可接受的盐。
11.按照权利要求1的化合物,它是2,3-二羟基丙酸雷帕霉素42-酯或其药学上可接受的盐。
12.按照权利要求1的化合物,它是2,2-二甲基[1,3]二噁烷-5-羧酸雷帕霉素42-酯或其药学上可接受的盐。
13.按照权利要求1的化合物,它是3-羟基-2-羟甲基丙酸雷帕霉素42-酯或其药学上可接受的盐。
14.按照权利要求1的化合物,它是2,2,5-三甲基[1,3]二噁烷-5-羧酸雷帕霉素42-酯或其药学上可接受的盐。
15.按照权利要求1的化合物,它是2,2-双(羟甲基)丙酸雷帕霉素42-酯或其药学上可接受的盐。
16.按照权利要求1的化合物,它是2,2-二甲基-5-(2-三甲基硅烷基乙氧甲基)[1,3]二噁烷-5-羧酸雷帕霉素42-酯或其药学上可接受的盐。
17.按照权利要求1的化合物,它是3-甲基-1,5-二氧杂-螺[5.5]十一烷-3-羧酸雷帕霉素42-酯或其药学上可接受的盐。
18.按照权利要求1的化合物,它是3-甲基-1,5-二氧杂-螺[5.5]十一烷-3-羧酸雷帕霉素31,42-二酯或其药学上可接受的盐。
19.权利要求1的化合物的应用,用于制备治疗哺乳动物的移植排斥、宿主移植物疾病、真菌感染、风湿性关节炎、再狭窄或肺炎的药物
20.药物组合物,它包含权利要求1的化合物或其药学上可接受的盐和药物载体。
21.制备权利要求1的式I雷帕霉素羟基酯的方法,包括:a)用酰化剂酰化雷帕霉素或其官能衍生物或类似物;或b)用两种酰化剂连续酰化雷帕霉素或其官能衍生物或类似物;所述酰化剂选自下式酸或其活性衍生物:
HO-CO(CR3R4)b(CR5R6)dCR7R8R9 (II)其中R3-R9、b和d定义如权利要求1,条件是假如需要用适当的保护基保护雷帕霉素或其官能衍生物的42位的话,应保护游离羟基,需要的话,反应后除去任何保护基。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/229,261 | 1994-04-18 | ||
US08/229,261 US5362718A (en) | 1994-04-18 | 1994-04-18 | Rapamycin hydroxyesters |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1149296A CN1149296A (zh) | 1997-05-07 |
CN1059905C true CN1059905C (zh) | 2000-12-27 |
Family
ID=22860462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN95193325A Expired - Lifetime CN1059905C (zh) | 1994-04-18 | 1995-04-14 | 雷怕霉素羟基酯,它们的制备方法及其药用组合物 |
Country Status (30)
Country | Link |
---|---|
US (2) | US5362718A (zh) |
EP (3) | EP1266899B1 (zh) |
JP (1) | JP3725901B2 (zh) |
KR (1) | KR100330800B1 (zh) |
CN (1) | CN1059905C (zh) |
AT (3) | ATE350384T1 (zh) |
BR (1) | BR9507323A (zh) |
CA (1) | CA2187024C (zh) |
CY (2) | CY2378B1 (zh) |
CZ (1) | CZ284567B6 (zh) |
DE (3) | DE122008000023I1 (zh) |
DK (2) | DK1266899T3 (zh) |
ES (3) | ES2191704T7 (zh) |
FR (1) | FR08C0018I2 (zh) |
HK (2) | HK1048816B (zh) |
HU (1) | HU225915B1 (zh) |
IL (1) | IL113179A (zh) |
LU (1) | LU91438I2 (zh) |
LV (1) | LV13038B (zh) |
MX (1) | MX9604694A (zh) |
NL (1) | NL300348I2 (zh) |
NZ (1) | NZ283988A (zh) |
PL (1) | PL183178B1 (zh) |
PT (2) | PT1266899E (zh) |
RU (1) | RU2134267C1 (zh) |
SI (2) | SI0763039T1 (zh) |
SK (1) | SK281787B6 (zh) |
TW (1) | TW275631B (zh) |
WO (1) | WO1995028406A1 (zh) |
ZA (1) | ZA953090B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103140494A (zh) * | 2010-08-04 | 2013-06-05 | 美利奴生命科学有限公司 | 制备具有抗增殖特性的新的42-o-(杂烷氧基烷基)雷帕霉素化合物的方法 |
CN104086564A (zh) * | 2014-07-30 | 2014-10-08 | 江苏奥赛康药业股份有限公司 | 一种高纯度坦罗莫司的制备方法 |
Families Citing this family (327)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6281015B1 (en) | 1994-12-16 | 2001-08-28 | Children's Medical Center Corp. | Localized delivery of factors enhancing survival of transplanted cells |
US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
US5780462A (en) * | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
GB9606452D0 (en) * | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
US5922730A (en) * | 1996-09-09 | 1999-07-13 | American Home Products Corporation | Alkylated rapamycin derivatives |
US6273913B1 (en) * | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
US8790391B2 (en) | 1997-04-18 | 2014-07-29 | Cordis Corporation | Methods and devices for delivering therapeutic agents to target vessels |
US6984635B1 (en) * | 1998-02-13 | 2006-01-10 | Board Of Trustees Of The Leland Stanford Jr. University | Dimerizing agents, their production and use |
US6015809A (en) * | 1998-08-17 | 2000-01-18 | American Home Products Corporation | Photocyclized rapamycin |
US6331547B1 (en) | 1999-08-18 | 2001-12-18 | American Home Products Corporation | Water soluble SDZ RAD esters |
TWI256395B (en) * | 1999-09-29 | 2006-06-11 | Wyeth Corp | Regioselective synthesis of rapamycin derivatives |
US6277983B1 (en) | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
US8236048B2 (en) | 2000-05-12 | 2012-08-07 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US6670355B2 (en) | 2000-06-16 | 2003-12-30 | Wyeth | Method of treating cardiovascular disease |
PT1318837E (pt) | 2000-08-11 | 2004-12-31 | Wyeth Corp | Metodo de tratamenton de carcinoma positivo a receptor de estrogenio |
DK1319008T3 (da) | 2000-09-19 | 2009-02-09 | Wyeth Corp | Vandoplöselige rapamycinestere |
US6399625B1 (en) | 2000-09-27 | 2002-06-04 | Wyeth | 1-oxorapamycins |
CA2424029C (en) | 2000-09-29 | 2008-01-29 | Cordis Corporation | Coated medical devices |
US20060222756A1 (en) * | 2000-09-29 | 2006-10-05 | Cordis Corporation | Medical devices, drug coatings and methods of maintaining the drug coatings thereon |
US20070276476A1 (en) * | 2000-09-29 | 2007-11-29 | Llanos Gerard H | Medical Devices, Drug Coatings and Methods for Maintaining the Drug Coatings Thereon |
US6440991B1 (en) | 2000-10-02 | 2002-08-27 | Wyeth | Ethers of 7-desmethlrapamycin |
US6399626B1 (en) * | 2000-10-02 | 2002-06-04 | Wyeth | Hydroxyesters of 7-desmethylrapamycin |
TWI286074B (en) | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
BR0115715A (pt) * | 2000-11-28 | 2004-02-03 | Wyeth Corp | Análise de expressão de ácidos nucleìcos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
PT2762140T (pt) | 2001-02-19 | 2017-07-04 | Novartis Ag | Resumo |
TWI233359B (en) * | 2001-04-06 | 2005-06-01 | Wyeth Corp | Pharmaceutical composition for treating neoplasm |
TWI296196B (en) * | 2001-04-06 | 2008-05-01 | Wyeth Corp | Antineoplastic combinations |
IL157898A0 (en) * | 2001-04-06 | 2004-03-28 | Wyeth Corp | Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil |
ZA200603888B (en) * | 2001-06-01 | 2007-05-30 | Wyeth Corp | Antineoplastic combinations |
UA77200C2 (en) | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
CN1310908C (zh) | 2001-08-22 | 2007-04-18 | 惠氏公司 | 雷帕霉素29-烯醇 |
BR0211905A (pt) * | 2001-08-22 | 2004-09-21 | Wyeth Corp | Dialdeìdos de rapamicina |
US7682387B2 (en) | 2002-04-24 | 2010-03-23 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
US6939376B2 (en) * | 2001-11-05 | 2005-09-06 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
IL162734A0 (en) | 2002-02-01 | 2005-11-20 | Ariad Gene Therapeutics Inc | Phosphorus-containing compounds & uses thereof |
US20040024450A1 (en) * | 2002-04-24 | 2004-02-05 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
DE60324416D1 (de) | 2002-05-16 | 2008-12-11 | Novartis Ag | Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie |
KR101086533B1 (ko) * | 2002-05-24 | 2011-11-23 | 쉐링 코포레이션 | 중화 사람 항-igfr 항체, 이를 제조하는 방법 및 이를 포함하는 조성물 |
NZ536558A (en) | 2002-05-27 | 2006-07-28 | Novartis Ag | Bis-aromatic alkanols |
WO2003106622A2 (en) * | 2002-05-30 | 2003-12-24 | The Children's Hospital Of Philadelphia | Methods for treatment of acute lymphocytic leukemia |
EP1655372A3 (en) | 2002-07-16 | 2008-01-16 | Biotica Technology Limited | Production of polyketides and other natural products |
RU2344821C2 (ru) * | 2002-07-30 | 2009-01-27 | Уайт | Парентеральные композиции, содержащие гидроксиэфиры рапамицина |
AU2003259803B2 (en) * | 2002-08-12 | 2007-08-02 | The Regents Of The University Of Michigan | Diagnosis and treatment of tuberous sclerosis |
KR20050084559A (ko) * | 2002-09-17 | 2005-08-26 | 와이어쓰 | 경구 제형 |
US20070078513A1 (en) * | 2002-09-18 | 2007-04-05 | Medtronic Vascular, Inc. | Controllable drug releasing gradient coatings for medical devices |
RU2478378C2 (ru) | 2002-09-24 | 2013-04-10 | Новартис Аг | Органические соединения |
AU2003293529A1 (en) | 2002-12-16 | 2004-07-29 | Nitromed, Inc. | Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use |
ES2395082T3 (es) * | 2003-01-27 | 2013-02-08 | Endocyte, Inc. | Conjugado de folato-vinblastina como medicamento |
AR042938A1 (es) * | 2003-02-06 | 2005-07-06 | Wyeth Corp | Uso del cci-779 en el tratamiento de la fibrosis hepatica |
UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
EP1615640B1 (en) * | 2003-04-22 | 2007-01-24 | Wyeth | Antineoplastic combinations |
BRPI0409681A (pt) * | 2003-04-23 | 2006-04-18 | Wyeth Corp | derivados de wortmanina solúveis em água |
US7160867B2 (en) * | 2003-05-16 | 2007-01-09 | Isotechnika, Inc. | Rapamycin carbohydrate derivatives |
US7417065B2 (en) | 2003-05-19 | 2008-08-26 | Irm Llc | Immunosuppressant compounds and compositions |
MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
TW200500065A (en) * | 2003-05-21 | 2005-01-01 | Wyeth Corp | Antiarthritic combinations |
JP4644663B2 (ja) * | 2003-06-03 | 2011-03-02 | セル ジェネシス インコーポレイテッド | ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法 |
US20050136035A1 (en) * | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
CA2528173A1 (en) * | 2003-07-16 | 2005-02-03 | Wyeth | Cci-779 isomer c |
CN1829514A (zh) * | 2003-07-25 | 2006-09-06 | 惠氏公司 | Cci-779冻干制剂 |
ES2287772T3 (es) * | 2003-08-07 | 2007-12-16 | Wyeth | Sintesis regioselectiva de cci-779. |
SG145716A1 (en) * | 2003-09-03 | 2008-09-29 | Wyeth Corp | Amorphous rapamycin 42-ester with 3-hydroxy-2- (hydroxymethyl)-2- methylpropionic acid and pharmaceutical compositions containing the same |
AR046194A1 (es) * | 2003-11-04 | 2005-11-30 | Mayo Foundation | Metodo de tratamiento del linfoma de celulas del manto |
US7220755B2 (en) | 2003-11-12 | 2007-05-22 | Biosensors International Group, Ltd. | 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same |
TW200526684A (en) * | 2003-11-21 | 2005-08-16 | Schering Corp | Anti-IGFR1 antibody therapeutic combinations |
DE602004011398T2 (de) * | 2004-01-08 | 2009-01-15 | Wyeth | Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779 |
AR047988A1 (es) * | 2004-03-11 | 2006-03-15 | Wyeth Corp | Combinaciones antineoplásicas de cci-779 y rituximab |
BRPI0509580A (pt) * | 2004-03-30 | 2007-11-27 | Pfizer Prod Inc | combinações de inibidores de transdução de sinal |
AU2005238431A1 (en) * | 2004-04-14 | 2005-11-10 | Wyeth | Regiospecific synthesis of rapamycin 42-ester derivatives |
DE602005010228D1 (de) | 2004-04-14 | 2008-11-20 | Wyeth Corp | Verfahren zur herstellung von rapamycin-42-estern und fk-506-32-estern mit dicarbonsäure, vorstufen für rapamycinkonjugate und antikörper |
AU2005233612A1 (en) | 2004-04-14 | 2005-10-27 | Wyeth | Proline CCI-779 (proline-rapamycin 42-ester with 2,2-bis (hydroxymethyl) propionic acid) and two-step enzymatic synthesis of proline CCI-779 and CCI-779 using microbial lipase |
CA2562164A1 (en) * | 2004-04-27 | 2005-11-10 | Wyeth | Labeling of rapamycin using rapamycin-specific methylases |
US20110104186A1 (en) | 2004-06-24 | 2011-05-05 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
WO2006017325A2 (en) * | 2004-07-13 | 2006-02-16 | Cell Genesys, Inc. | Aav vector compositions and methods for enhanced expression of immunoglobulins the same |
WO2006012527A1 (en) | 2004-07-23 | 2006-02-02 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
JP2008517874A (ja) * | 2004-08-10 | 2008-05-29 | ワイス | Cci−779誘導体及びそれらの作製法 |
GB0417852D0 (en) | 2004-08-11 | 2004-09-15 | Biotica Tech Ltd | Production of polyketides and other natural products |
US7901451B2 (en) | 2004-09-24 | 2011-03-08 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
CA2582374A1 (en) * | 2004-10-04 | 2006-04-20 | Qlt Usa, Inc. | Ocular delivery of polymeric delivery formulations |
US8313763B2 (en) * | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
US20080221660A1 (en) * | 2004-10-28 | 2008-09-11 | Medtronic Vascular, Inc. | Platelet Gel for Treatment of Aneurysms |
CN101048152A (zh) * | 2004-10-28 | 2007-10-03 | 惠氏公司 | mTOR抑制剂在治疗子宫平滑肌瘤中的应用 |
US8021849B2 (en) * | 2004-11-05 | 2011-09-20 | Siemens Healthcare Diagnostics Inc. | Methods and kits for the determination of sirolimus in a sample |
CN102886045A (zh) | 2005-02-03 | 2013-01-23 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
CA2595766A1 (en) * | 2005-02-09 | 2006-08-17 | Wyeth | Cci-779 polymorph and use thereof |
AU2006214021A1 (en) * | 2005-02-15 | 2006-08-24 | Wyeth | Orally bioavailable CCI-779 tablet formulations |
GB0503936D0 (en) | 2005-02-25 | 2005-04-06 | San Raffaele Centro Fond | Method |
CN101133066A (zh) * | 2005-03-02 | 2008-02-27 | 惠氏公司 | 从母液中回收cci-779 |
US20100047338A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
EP1853612A1 (en) * | 2005-03-02 | 2007-11-14 | Wyeth | Purification of rapamycin |
GB0504544D0 (en) | 2005-03-04 | 2005-04-13 | Novartis Ag | Organic compounds |
US20100061994A1 (en) * | 2005-03-11 | 2010-03-11 | Rose Mary Sheridan | Medical uses of 39-desmethoxyrapamycin and analogues thereof |
EP1896018A2 (en) | 2005-03-11 | 2008-03-12 | Biotica Technology Limited | Medical uses of 39-desmethoxyrapamycin and analogues thereof |
GB0504994D0 (en) * | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
EP1863816B1 (en) * | 2005-03-16 | 2014-06-25 | Endocyte, Inc. | Synthesis and purification of pteroic acid and conjugates thereof |
AU2006236637B2 (en) * | 2005-04-15 | 2012-09-06 | Merck Sharp & Dohme Corp. | Methods and compositions for treating or preventing cancer |
US7189582B2 (en) * | 2005-04-27 | 2007-03-13 | Dade Behring Inc. | Compositions and methods for detection of sirolimus |
US20070004767A1 (en) * | 2005-06-30 | 2007-01-04 | Gutmann David H | Methods for treating neurofibromatosis 1 |
WO2007011707A2 (en) | 2005-07-15 | 2007-01-25 | Micell Technologies, Inc. | Polymer coatings containing drug powder of controlled morphology |
WO2007011708A2 (en) | 2005-07-15 | 2007-01-25 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
US7632509B2 (en) * | 2005-07-19 | 2009-12-15 | Biosante Pharmaceuticals, Inc. | Methods to express recombinant proteins from lentiviral vectors |
HUE026303T2 (hu) | 2005-07-25 | 2016-06-28 | Emergent Product Dev Seattle | B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával |
ES2468240T3 (es) | 2005-08-19 | 2014-06-16 | Endocyte, Inc. | Conjugados de ligando de múltiples fármacos |
EP1933845A2 (en) | 2005-08-25 | 2008-06-25 | Medtronic Vascular, Inc. | Nitric oxide-releasing biodegradable polymers useful as medical devices and coatings therefore |
ES2611307T3 (es) | 2005-08-30 | 2017-05-08 | University Of Miami | Inmunomodulación de agonistas, antagonistas e inmunotoxinas del receptor del factor de necrosis tumoral 25 (TNFR25) |
US7538119B2 (en) * | 2005-11-04 | 2009-05-26 | Wyeth | 41-Methoxy isotope labeled rapamycin 42-ester |
EP1942937A1 (en) | 2005-11-04 | 2008-07-16 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
BRPI0619493A2 (pt) * | 2005-12-07 | 2016-09-06 | Wyeth Corp | forma cristalina purificada de cci-779, processo para a purificação de cc-779, produto, método para monitorar a cristalização de cci-779, kit, composição farmacêutica, método para o tratamento de câncer, e, uso de um cci-779 purificado |
EP1957964A2 (en) * | 2005-12-07 | 2008-08-20 | Wyeth Pharmaceuticals | Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry |
AU2006322024A1 (en) * | 2005-12-07 | 2007-06-14 | Wyeth | Scalable process for the preparation of a rapamycin 42-ester from a rapamycin 42-ester boronate |
SI1983984T1 (en) * | 2006-02-02 | 2018-06-29 | Novartis Ag | Treatment of tuberous sclerosis |
US20070203169A1 (en) * | 2006-02-28 | 2007-08-30 | Zhao Jonathon Z | Isomers and 42-epimers of rapamycin ester analogs, methods of making and using the same |
AR059740A1 (es) * | 2006-03-07 | 2008-04-23 | Wyeth Corp | Procesos para preparar conjugados de polietilen glicol solubles en agua de inmunosupresores macrolidos |
DE102006011507A1 (de) * | 2006-03-14 | 2007-09-20 | Lts Lohmann Therapie-Systeme Ag | Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine |
US20070292922A1 (en) * | 2006-03-31 | 2007-12-20 | Cell Genesys, Inc. | Regulated expression of recombinant proteins from adeno-associated viral vectors |
PL2019657T3 (pl) | 2006-04-26 | 2015-10-30 | Micell Technologies Inc | Powłoki zawierające wiele leków |
US8241619B2 (en) | 2006-05-15 | 2012-08-14 | Medtronic Vascular, Inc. | Hindered amine nitric oxide donating polymers for coating medical devices |
GB0609962D0 (en) * | 2006-05-19 | 2006-06-28 | Biotica Tech Ltd | Novel compounds |
GB0609963D0 (en) * | 2006-05-19 | 2006-06-28 | Biotica Tech Ltd | Novel compounds |
AU2007315790A1 (en) * | 2006-06-30 | 2008-05-08 | Interface Biologics, Inc. | Bioresponsive polymers |
US20080207671A1 (en) * | 2006-07-31 | 2008-08-28 | The Regents Of The University Of Michigan | Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway |
US20100266590A1 (en) * | 2006-08-02 | 2010-10-21 | Demetri George D | Combination therapy |
RU2010104916A (ru) * | 2006-08-16 | 2011-08-20 | Михаил В. Благосклонный (US) | Способ профилактики и лечения возрастных заболеваний |
US20080051691A1 (en) * | 2006-08-28 | 2008-02-28 | Wyeth | Implantable shunt or catheter enabling gradual delivery of therapeutic agents |
EP2702993B1 (en) | 2006-09-13 | 2017-12-06 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
TW200824713A (en) * | 2006-10-18 | 2008-06-16 | Wyeth Corp | Processes for the synthesis of individual isomers of mono-PEG CCI-779 |
US20080097591A1 (en) * | 2006-10-20 | 2008-04-24 | Biosensors International Group | Drug-delivery endovascular stent and method of use |
US8067055B2 (en) | 2006-10-20 | 2011-11-29 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method of use |
US7691402B2 (en) * | 2006-11-06 | 2010-04-06 | Medtronic Vascular, Inc. | Block biodegradable copolymers for medical devices |
US20080242648A1 (en) * | 2006-11-10 | 2008-10-02 | Syndax Pharmaceuticals, Inc., A California Corporation | COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER |
US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
US8430055B2 (en) | 2008-08-29 | 2013-04-30 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US20080175887A1 (en) | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
CN101522691B (zh) * | 2006-11-27 | 2012-08-22 | 泰尔茂株式会社 | O-烷基化雷帕霉素衍生物的制备方法及o-烷基化雷帕霉素衍生物 |
CA2679712C (en) | 2007-01-08 | 2016-11-15 | Micell Technologies, Inc. | Stents having biodegradable layers |
US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
US7753962B2 (en) * | 2007-01-30 | 2010-07-13 | Medtronic Vascular, Inc. | Textured medical devices |
WO2008094181A2 (en) * | 2007-02-01 | 2008-08-07 | The Regents Of The University Of Michigan | Compositions and methods for detecting, preventing and treating seizures and seizure related disorders |
WO2008101231A2 (en) | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
US7815927B2 (en) * | 2007-03-08 | 2010-10-19 | Medtronic Vascular, Inc. | Terpolymers for controlled release of bioactive agents from implantable medical devices |
US7811600B2 (en) * | 2007-03-08 | 2010-10-12 | Medtronic Vascular, Inc. | Nitric oxide donating medical devices and methods of making same |
EP2489372A3 (en) | 2007-03-14 | 2013-01-02 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
US20080245375A1 (en) * | 2007-04-05 | 2008-10-09 | Medtronic Vascular, Inc. | Benign Prostatic Hyperplasia Treatments |
TW200845960A (en) * | 2007-04-05 | 2008-12-01 | Wyeth Corp | Wortmannin-rapalog conjugate and uses thereof |
TW200901989A (en) | 2007-04-10 | 2009-01-16 | Wyeth Corp | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
US20080306581A1 (en) * | 2007-06-07 | 2008-12-11 | Medtronic Vascular, Inc. | Streamlined Stents |
CA2690943A1 (en) | 2007-06-25 | 2008-12-31 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
US8852620B2 (en) | 2007-07-20 | 2014-10-07 | Medtronic Vascular, Inc. | Medical devices comprising polymeric drug delivery systems with drug solubility gradients |
US8273828B2 (en) * | 2007-07-24 | 2012-09-25 | Medtronic Vascular, Inc. | Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation |
US20090043378A1 (en) * | 2007-08-10 | 2009-02-12 | Medtronic Vascular, Inc. | Biocompatible Polymer System for Extended Drug Release |
US20090076060A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched temsirolimus |
KR100930167B1 (ko) * | 2007-09-19 | 2009-12-07 | 삼성전기주식회사 | 초광각 광학계 |
US20110091508A1 (en) | 2007-10-05 | 2011-04-21 | Interface Biologics ,Inc. | Oligofluorinated cross-linked polymers and uses thereof |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
CA2703017C (en) | 2007-10-19 | 2017-04-25 | Roseita Esfand | Self-eliminating coatings |
US20090131367A1 (en) * | 2007-11-19 | 2009-05-21 | The Regents Of The University Of Colorado | Combinations of HDAC Inhibitors and Proteasome Inhibitors |
CA2711765A1 (en) * | 2008-01-11 | 2009-07-16 | Massachusetts Eye & Ear Infirmary | Conditional-stop dimerizable caspase transgenic animals |
US20090222088A1 (en) * | 2008-02-29 | 2009-09-03 | Medtronic Vascular, Inc. | Secondary Amine Containing Nitric Oxide Releasing Polymer Composition |
US20090232868A1 (en) * | 2008-03-17 | 2009-09-17 | Medtronic Vascular, Inc. | Nitric Oxide Releasing Polymer Composition |
US20090232863A1 (en) * | 2008-03-17 | 2009-09-17 | Medtronic Vascular, Inc. | Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers |
US20090240323A1 (en) * | 2008-03-20 | 2009-09-24 | Medtronic Vascular, Inc. | Controlled Degradation of Magnesium Stents |
WO2009117669A2 (en) | 2008-03-21 | 2009-09-24 | The University Of Chicago | Treatment with opioid antagonists and mtor inhibitors |
US20090253733A1 (en) * | 2008-04-02 | 2009-10-08 | Biointeractions, Ltd. | Rapamycin carbonate esters |
DK2132228T3 (da) | 2008-04-11 | 2011-10-10 | Emergent Product Dev Seattle | CD37-immunterapeutisk middel og kombination med bifunktionelt kemoterapeutisk middel deraf |
US20110098241A1 (en) * | 2008-04-14 | 2011-04-28 | Poniard Pharmaceuticals, Inc. | Rapamycin analogs as anti-cancer agents |
CN102083397B (zh) | 2008-04-17 | 2013-12-25 | 米歇尔技术公司 | 具有生物可吸收层的支架 |
US20090269480A1 (en) * | 2008-04-24 | 2009-10-29 | Medtronic Vascular, Inc. | Supercritical Fluid Loading of Porous Medical Devices With Bioactive Agents |
US20090297576A1 (en) * | 2008-06-02 | 2009-12-03 | Medtronic Vascular, Inc. | Local Delivery of PAR-1 Antagonists to Treat Vascular Complications |
US20090299464A1 (en) * | 2008-06-02 | 2009-12-03 | Medtronic Vascular, Inc. | Reducing Bioabsorbtion Time of Polymer Coated Implantable Medical Devices Using Polymer Blends |
PL2310011T3 (pl) | 2008-06-17 | 2013-12-31 | Wyeth Llc | Kombinacje przeciwnowotworowe zawierające HKI-272 i vinorelbine |
EP2303250A1 (en) | 2008-06-20 | 2011-04-06 | Novartis AG | Paediatric compositions for treating1 multiple sclerosis |
US9486431B2 (en) | 2008-07-17 | 2016-11-08 | Micell Technologies, Inc. | Drug delivery medical device |
CN101676291B (zh) | 2008-09-18 | 2012-05-09 | 上海海和药物研究开发有限公司 | 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途 |
KR20110074758A (ko) * | 2008-10-03 | 2011-07-01 | 엘릭서 메디컬 코포레이션 | 마크로사이클릭 락톤 화합물 및 이를 사용하는 방법 |
US20100092535A1 (en) * | 2008-10-10 | 2010-04-15 | Medtronic Vascular, Inc. | Nanoporous Drug Delivery System |
US20100092534A1 (en) * | 2008-10-10 | 2010-04-15 | Medtronic Vascular, Inc. | Combination Local Delivery Using a Stent |
CN104042612A (zh) | 2008-11-11 | 2014-09-17 | 得克萨斯大学体系董事会 | 哺乳动物雷帕霉素靶蛋白的抑制 |
US20100131051A1 (en) * | 2008-11-24 | 2010-05-27 | Medtronic Vascular, Inc. | Systems and Methods for Treatment of Aneurysms Using Zinc Chelator(s) |
US20100131001A1 (en) * | 2008-11-24 | 2010-05-27 | Medtronic Vascular, Inc. | Targeted Drug Delivery for Aneurysm Treatment |
US20100152832A1 (en) * | 2008-12-12 | 2010-06-17 | Medtronic Vascular, Inc. | Apparatus and Methods for Treatment of Aneurysms With Fibrin Derived Peptide B-Beta |
KR20110112352A (ko) | 2008-12-18 | 2011-10-12 | 노파르티스 아게 | 1-(4-{l-[(e)-4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노]-에틸}-2-에틸-벤질)-아제티딘-3-카르복실산의 신규한 다형체 형태 |
EP2379499B1 (en) | 2008-12-18 | 2014-04-09 | Novartis AG | Hydrochloride salt of 1-(4-(1-((E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl)-2-ethyl-benzyl)-azetidine-3-carboxylic acid |
US20120115840A1 (en) | 2008-12-18 | 2012-05-10 | Lech Ciszewski | Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid |
US8158187B2 (en) * | 2008-12-19 | 2012-04-17 | Medtronic Vascular, Inc. | Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices |
US20100198338A1 (en) * | 2009-01-30 | 2010-08-05 | Medtronic Vascular, Inc., A Delaware Corporation | Hydrogen Sulfide Donating Polymers |
CN102686600A (zh) | 2009-02-05 | 2012-09-19 | 托凯药业股份有限公司 | 甾体cyp17抑制剂/抗雄激素物质的新型药物前体 |
US20100227799A1 (en) * | 2009-03-09 | 2010-09-09 | Medtronic Vascular, Inc. | Simultaneous photodynamic therapy and photo induced polymerization |
US9981072B2 (en) | 2009-04-01 | 2018-05-29 | Micell Technologies, Inc. | Coated stents |
US8236341B2 (en) * | 2009-04-02 | 2012-08-07 | Medtronic Vascular, Inc. | Poly(tetrafluoroethylene) polymer with nitric oxide donating surface |
US20100256728A1 (en) * | 2009-04-07 | 2010-10-07 | Medtronic Vascular, Inc. | Semi-Permiable Biodegradable Stent Graft and Uses Thereof |
US8709465B2 (en) * | 2009-04-13 | 2014-04-29 | Medtronic Vascular, Inc. | Diazeniumdiolated phosphorylcholine polymers for nitric oxide release |
CA2758297A1 (en) | 2009-04-16 | 2010-10-21 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
WO2010121187A2 (en) | 2009-04-17 | 2010-10-21 | Micell Techologies, Inc. | Stents having controlled elution |
US8716307B2 (en) | 2009-05-13 | 2014-05-06 | The Trustees Of The University Of Pennsylvania | Combination antineoplastic therapy |
EP2453834A4 (en) | 2009-07-16 | 2014-04-16 | Micell Technologies Inc | MEDICAL DEVICE DISPENSING MEDICINE |
EP2462165B1 (en) | 2009-08-03 | 2016-05-11 | University of Miami | Method for in vivo expansion of t regulatory cells |
WO2011051960A2 (en) | 2009-09-25 | 2011-05-05 | Cadila Healthcare Limited | Process for the preparation of rapamycin derivatives |
AU2010310786B2 (en) | 2009-10-23 | 2014-03-27 | Eli Lilly And Company | AKT inhibitors |
EP2762142A1 (en) | 2009-10-30 | 2014-08-06 | ARIAD Pharmaceuticals, Inc. | Compositions for treating cancer |
US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
JP2013514278A (ja) | 2009-12-18 | 2013-04-25 | インターフェース バイオロジクス,インコーポレーテッド | 自己集合コーティングからの薬物の局所送達 |
US8182830B2 (en) * | 2010-01-05 | 2012-05-22 | Medtronic Vascular, Inc. | Hydrogen sulfide generating polymers |
AU2011210227A1 (en) * | 2010-01-28 | 2012-08-30 | Fresenius Kabi Oncology Ltd. | Process for the preparation of Temsirolimus and its intermediates |
EP2531140B1 (en) | 2010-02-02 | 2017-11-01 | Micell Technologies, Inc. | Stent and stent delivery system with improved deliverability |
US20130195919A1 (en) | 2010-03-05 | 2013-08-01 | President And Fellows Of Harvard College | Induced dendritic cell compositions and uses thereof |
US10232092B2 (en) | 2010-04-22 | 2019-03-19 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
EP2563391B1 (en) | 2010-04-27 | 2020-08-26 | Roche Glycart AG | Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor |
WO2011151704A2 (en) | 2010-06-02 | 2011-12-08 | Fresenius Kabi Oncology Ltd. | Stable pharmaceutical compositions of rapamycin esters |
CA2805631C (en) | 2010-07-16 | 2018-07-31 | Micell Technologies, Inc. | Drug delivery medical device |
EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
JP2014503500A (ja) | 2010-11-18 | 2014-02-13 | シンタ ファーマスーティカルズ コーポレーション | 低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択 |
CN103327976A (zh) | 2010-11-18 | 2013-09-25 | 辛塔医药品有限公司 | 基于缺氧状态预选受试者以用于治疗性治疗 |
ES2423798T3 (es) | 2010-11-19 | 2013-09-24 | Universitätsklinikum Freiburg | Hidrogeles de PEG disolubles sensibles a estímulos biofuncionalizados |
CN102020662B (zh) | 2011-01-07 | 2013-02-13 | 天津市炜杰科技有限公司 | 一种驮瑞塞尔制备方法 |
ES2547916T3 (es) | 2011-02-18 | 2015-10-09 | Novartis Pharma Ag | Terapia de combinación de inhibidores de mTOR/JAK |
BR112013025085A2 (pt) * | 2011-04-01 | 2016-07-19 | Sandoz Ag | processo para a acilação de rapamicina e processo para sintetizar tensirolimo |
CN103732592A (zh) | 2011-04-21 | 2014-04-16 | 默沙东公司 | 胰岛素样生长因子-1受体抑制剂 |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
CA2838387A1 (en) | 2011-06-06 | 2012-12-13 | Chevron Phillips Chemical Company Lp | Use of metallocene compounds for cancer treatment |
EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
US10117972B2 (en) | 2011-07-15 | 2018-11-06 | Micell Technologies, Inc. | Drug delivery medical device |
WO2013013708A1 (en) | 2011-07-26 | 2013-01-31 | Fundació Institut D'investigació Biomèdica De Bellvitge | Treatment of acute rejection in renal transplant |
US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
CN102424829B (zh) * | 2011-10-26 | 2013-10-16 | 苏州汉酶生物技术有限公司 | 一种酶催化合成坦西莫司的方法 |
AU2012351728A1 (en) | 2011-12-16 | 2014-06-19 | Oncology Institute Of Southern Switzerland | Combination of inotuzumab ozogamicin and torisel for the treatment of cancer |
GB201122305D0 (en) | 2011-12-23 | 2012-02-01 | Biotica Tech Ltd | Novel compound |
US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
CN102796115B (zh) * | 2012-05-25 | 2015-07-15 | 上海现代制药股份有限公司 | 一种坦西莫司的制备方法 |
CN103705925B (zh) | 2012-09-29 | 2018-03-30 | 段磊 | 抑制PI3K/AKT/mTOR信号通路的药物组合 |
US9750728B2 (en) | 2012-09-29 | 2017-09-05 | Targeted Therapeutics, Llc | Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway |
US20150290176A1 (en) | 2012-10-12 | 2015-10-15 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors to treat vascular cognitive impairment |
WO2014062697A2 (en) | 2012-10-16 | 2014-04-24 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
EP2914260A1 (en) | 2012-10-31 | 2015-09-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
CA2897826C (en) | 2013-01-09 | 2022-09-27 | Taylor H. Schreiber | Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein |
DK3300745T3 (da) | 2013-02-15 | 2019-11-04 | Univ California | Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf |
EP2967803B1 (en) | 2013-03-12 | 2023-12-27 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
US20160030401A1 (en) | 2013-03-13 | 2016-02-04 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors for prevention of intestinal polyp growth and cancer |
CA2904170A1 (en) | 2013-03-14 | 2014-09-25 | University Of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
EP2994758B1 (en) | 2013-05-08 | 2017-12-20 | Opthea Limited | Biomarkers for age-related macular degeneration (amd) |
WO2014186532A1 (en) | 2013-05-15 | 2014-11-20 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
CN103421023B (zh) * | 2013-07-30 | 2015-09-23 | 福建省微生物研究所 | 一种替西罗莫司的合成工艺 |
CN105636594A (zh) | 2013-08-12 | 2016-06-01 | 托凯药业股份有限公司 | 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物 |
EA201690987A1 (ru) | 2013-11-13 | 2016-10-31 | Новартис Аг | Низкодозовые иммуностимулирующие ингибиторы mtor и их применения |
EP2878312A1 (en) | 2013-12-02 | 2015-06-03 | Albert-Ludwigs-Universität Freiburg | Reversible PEGylation of nanocarriers |
CA2931684C (en) | 2013-12-19 | 2024-02-20 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
US10287354B2 (en) | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
AU2014373683B2 (en) | 2013-12-31 | 2020-05-07 | Rapamycin Holdings, Llc | Oral rapamycin nanoparticle preparations and use |
US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
US10428331B2 (en) | 2014-01-16 | 2019-10-01 | Musc Foundation For Research Development | Targeted nanocarriers for the administration of immunosuppressive agents |
WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
EP3811970A1 (en) | 2014-03-15 | 2021-04-28 | Novartis AG | Regulatable chimeric antigen receptor |
US10300070B2 (en) | 2014-03-27 | 2019-05-28 | The Brigham And Women's Hospital, Inc. | Metabolically-activated drug conjugates to overcome resistance in cancer therapy |
CA2940671A1 (en) | 2014-04-07 | 2015-10-15 | Novartis Ag | Treatment of cancer using anti-cd19 chimeric antigen receptor |
EP3131546B1 (en) | 2014-04-16 | 2022-02-16 | Rapamycin Holdings, Inc. | Oral rapamycin preparation for use in treating feline chronic gingivo- stomatitis (fcgs) |
WO2015187541A1 (en) | 2014-06-02 | 2015-12-10 | Children's Medical Center Corporation | Methods and compositions for immunomodulation |
US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
EP3193915A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
SG10201913765YA (en) | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
EP4205749A1 (en) | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimized chimeric antigen receptor-containing cells |
WO2016025880A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
DK3183268T3 (da) | 2014-08-19 | 2020-05-11 | Univ Pennsylvania | Behandling af cancer ved anvendelse af en cd123-kimær antigenreceptor |
CN107073066B (zh) | 2014-09-11 | 2021-09-17 | 加利福尼亚大学董事会 | mTORC1抑制剂 |
CN114621969A (zh) | 2014-09-17 | 2022-06-14 | 诺华股份有限公司 | 用于过继免疫疗法的具有嵌合受体的靶向细胞毒性细胞 |
EP2997977A1 (en) | 2014-09-19 | 2016-03-23 | Fundación de la Comunidad Valenciana Centro de Investigación Principe Felipe | Specific mtor inhibitors in the treatment of x-linked adrenoleukodystrophy |
SG11201702895SA (en) | 2014-10-08 | 2017-05-30 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
US20190054117A1 (en) | 2014-12-19 | 2019-02-21 | Novartis Ag | Dimerization switches and uses thereof |
US10377818B2 (en) | 2015-01-30 | 2019-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating glioma |
ES2876974T3 (es) | 2015-04-07 | 2021-11-15 | Novartis Ag | Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina |
AU2016249005B2 (en) | 2015-04-17 | 2022-06-16 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
US10576076B2 (en) | 2015-05-20 | 2020-03-03 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
EP3303634B1 (en) | 2015-06-03 | 2023-08-30 | The Regents of The University of California | Cas9 variants and methods of use thereof |
WO2017029391A1 (en) | 2015-08-20 | 2017-02-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method for treating cancer |
KR20180080230A (ko) | 2015-11-11 | 2018-07-11 | 노파르티스 아게 | 미오스타틴 길항제의 용도, 이들을 함유하는 조합물 및 그의 용도 |
US10765665B2 (en) | 2015-11-24 | 2020-09-08 | Melin Jeffrey | Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases |
WO2020047527A2 (en) | 2018-09-02 | 2020-03-05 | F1 Bioventures, Llc | Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs |
CN109641947B (zh) | 2016-07-20 | 2023-04-14 | 犹他大学研究基金会 | Cd229 car t细胞及其使用方法 |
KR20190056401A (ko) | 2016-09-22 | 2019-05-24 | 머케이터 메드시스템즈, 인크. | 템시롤리무스를 사용하는 재협착의 치료 |
US10525083B2 (en) | 2016-10-07 | 2020-01-07 | Novartis Ag | Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain |
KR20190089005A (ko) | 2016-11-23 | 2019-07-29 | 노파르티스 아게 | 에베롤리무스, 닥톨리십 또는 둘 다를 사용하여 면역 반응을 증진시키는 방법 |
SG11201908226XA (en) | 2017-02-10 | 2019-10-30 | Mount Tam Therapeutics Inc | Rapamycin analog |
SG11201907814SA (en) | 2017-03-03 | 2019-09-27 | F1 Oncology Inc | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
US20210154372A1 (en) | 2017-05-15 | 2021-05-27 | C.R. Bard, Inc. | Medical device with drug-eluting coating and intermediate layer |
CN108948045A (zh) * | 2017-05-20 | 2018-12-07 | 鲁南制药集团股份有限公司 | 一种替西罗莫司的制备方法 |
US10576063B2 (en) * | 2017-05-26 | 2020-03-03 | Mercator Medsystems, Inc. | Combination therapy for treatment of restenosis |
EP3644997A1 (en) | 2017-06-26 | 2020-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of olmsted syndrome |
WO2019012024A1 (en) | 2017-07-13 | 2019-01-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | METHODS FOR INCREASING EXPANSION AND IMMUNOSUPPRESSIVE CAPACITY OF A CD8 + CD45RCBAS TREGS POPULATION / - |
UY37900A (es) | 2017-09-26 | 2019-04-30 | Novartis Ag | Nuevos derivados de rapamicina |
US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
US11654267B2 (en) | 2018-03-14 | 2023-05-23 | Mercator Medsystems, Inc. | Medical instrument and medical method for localized drug delivery |
WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
ES2945560T3 (es) | 2018-05-01 | 2023-07-04 | Revolution Medicines Inc | Análogos de rapamicina unidos en C40, C28 y C-32 como inhibidores de mTOR |
WO2019213282A1 (en) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
IL278335B1 (en) | 2018-05-01 | 2024-05-01 | Revolution Medicines Inc | C26-linked rapamycin analogs as MTOR inhibitors |
WO2019222843A1 (en) | 2018-05-22 | 2019-11-28 | Interface Biologics, Inc. | Compositions and methods for delivering drugs to a vessel wall |
CA3107349A1 (en) | 2018-07-23 | 2020-01-30 | Enclear Therapies, Inc. | Methods of treating neurological disorders |
WO2020023418A1 (en) | 2018-07-23 | 2020-01-30 | Enclear Therapies, Inc. | Methods of treating neurological disorders |
WO2020053125A1 (en) | 2018-09-10 | 2020-03-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of neurofibromatosis |
WO2020070289A1 (en) | 2018-10-05 | 2020-04-09 | St. Anna Kinderkrebsforschung | A group of chimeric antigen receptors (cars) |
EP3632461A1 (en) | 2018-10-05 | 2020-04-08 | St. Anna Kinderkrebsforschung | A group of chimeric antigen receptors (cars) |
EP3632460A1 (en) | 2018-10-05 | 2020-04-08 | St. Anna Kinderkrebsforschung | A group of chimeric antigen receptors (cars) |
KR20210075117A (ko) | 2018-10-05 | 2021-06-22 | 세인트 안나 킨더크렙스포르슝 | 키메라 항원 수용체(car) 그룹 |
JP7262581B2 (ja) | 2018-11-14 | 2023-04-21 | ルトニックス,インコーポレーテッド | 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス |
EP3903828A4 (en) | 2018-12-21 | 2022-10-05 | Daiichi Sankyo Company, Limited | COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND A KINASE INHIBITOR |
WO2020209828A1 (en) | 2019-04-08 | 2020-10-15 | Bard Peripheral Vascular, Inc. | Medical device with drug-eluting coating on modified device surface |
EP3952947A4 (en) | 2019-04-11 | 2024-07-03 | Enclear Therapies Inc | METHODS FOR IMPROVING CEREBRAL SPINAL FLUID AND DEVICES AND SYSTEMS THEREFOR |
CN113372359A (zh) * | 2020-03-10 | 2021-09-10 | 鲁南制药集团股份有限公司 | 一种坦西莫司的制备方法 |
EP4240356A1 (en) | 2020-11-03 | 2023-09-13 | RDiscovery, LLC | Therapies for treatment of cancer and phagocytosis-deficiency related diseases |
CA3223081A1 (en) | 2021-07-15 | 2023-01-19 | Samir Mitragotri | Compositions and methods relating to cells with adhered particles |
WO2024008799A1 (en) | 2022-07-06 | 2024-01-11 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of proliferative glomerulonephritis |
WO2024028433A1 (en) | 2022-08-04 | 2024-02-08 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of lymphoproliferative disorders |
WO2024100236A1 (en) | 2022-11-11 | 2024-05-16 | Astrazeneca Ab | Combination therapies for the treatment of cancer |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4650803A (en) * | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
WO1992005179A1 (en) * | 1990-09-19 | 1992-04-02 | American Home Products Corporation | Carboxylic acid esters of rapamycin |
US5233036A (en) * | 1990-10-16 | 1993-08-03 | American Home Products Corporation | Rapamycin alkoxyesters |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA737247B (en) * | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
US3993749A (en) * | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
US4885171A (en) * | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
US4316885A (en) * | 1980-08-25 | 1982-02-23 | Ayerst, Mckenna And Harrison, Inc. | Acyl derivatives of rapamycin |
US4401653A (en) * | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
US4375464A (en) * | 1981-11-19 | 1983-03-01 | Ayerst, Mckenna & Harrison Inc. | Antibiotic AY24,668 and process of preparation |
US5100899A (en) * | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
US5023264A (en) * | 1990-07-16 | 1991-06-11 | American Home Products Corporation | Rapamycin oximes |
US5023263A (en) * | 1990-08-09 | 1991-06-11 | American Home Products Corporation | 42-oxorapamycin |
US5023262A (en) * | 1990-08-14 | 1991-06-11 | American Home Products Corporation | Hydrogenated rapamycin derivatives |
US5378696A (en) * | 1990-09-19 | 1995-01-03 | American Home Products Corporation | Rapamycin esters |
US5130307A (en) * | 1990-09-28 | 1992-07-14 | American Home Products Corporation | Aminoesters of rapamycin |
US5221670A (en) * | 1990-09-19 | 1993-06-22 | American Home Products Corporation | Rapamycin esters |
US5080899A (en) * | 1991-02-22 | 1992-01-14 | American Home Products Corporation | Method of treating pulmonary inflammation |
US5078999A (en) * | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
US5120842A (en) * | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
IL101353A0 (en) * | 1991-04-03 | 1992-11-15 | American Home Prod | Pharmaceutical compositions for treating diabetes |
US5100883A (en) * | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
US5118678A (en) * | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
FI921595A (fi) | 1991-04-17 | 1992-10-18 | American Home Prod | Rapamycinkarbamater |
US5194447A (en) * | 1992-02-18 | 1993-03-16 | American Home Products Corporation | Sulfonylcarbamates of rapamycin |
US5091389A (en) * | 1991-04-23 | 1992-02-25 | Merck & Co., Inc. | Lipophilic macrolide useful as an immunosuppressant |
US5138051A (en) * | 1991-08-07 | 1992-08-11 | American Home Products Corporation | Rapamycin analogs as immunosuppressants and antifungals |
US5102876A (en) * | 1991-05-07 | 1992-04-07 | American Home Products Corporation | Reduction products of rapamycin |
US5118677A (en) * | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
EP0525960B1 (en) | 1991-06-18 | 1996-03-20 | American Home Products Corporation | Use of rapamycin for the treatment of adult T-cell leukemia/lymphoma |
IL102414A (en) | 1991-07-25 | 1996-08-04 | Univ Louisville Res Found | Medicinal preparations for the treatment of ocular inflammation, containing rapamycin |
US5169851A (en) * | 1991-08-07 | 1992-12-08 | American Home Products Corporation | Rapamycin analog as immunosuppressants and antifungals |
US5286730A (en) * | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
US5286731A (en) * | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory bowel disease |
US5151413A (en) * | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
US5177203A (en) * | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
US5302584A (en) * | 1992-10-13 | 1994-04-12 | American Home Products Corporation | Carbamates of rapamycin |
US5262423A (en) * | 1992-10-29 | 1993-11-16 | American Home Products Corporation | Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents |
US5260300A (en) * | 1992-11-19 | 1993-11-09 | American Home Products Corporation | Rapamycin carbonate esters as immuno-suppressant agents |
US5385908A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
TWI286074B (en) | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
-
1994
- 1994-04-18 US US08/229,261 patent/US5362718A/en not_active Ceased
- 1994-11-08 TW TW083110308A patent/TW275631B/zh not_active IP Right Cessation
-
1995
- 1995-03-29 IL IL113179A patent/IL113179A/en not_active IP Right Cessation
- 1995-04-13 ZA ZA953090A patent/ZA953090B/xx unknown
- 1995-04-14 PT PT02014322T patent/PT1266899E/pt unknown
- 1995-04-14 ES ES95915671.2T patent/ES2191704T7/es active Active
- 1995-04-14 ES ES02014322T patent/ES2277975T3/es not_active Expired - Lifetime
- 1995-04-14 KR KR1019960705839A patent/KR100330800B1/ko active IP Right Grant
- 1995-04-14 CA CA002187024A patent/CA2187024C/en not_active Expired - Lifetime
- 1995-04-14 NZ NZ283988A patent/NZ283988A/en not_active IP Right Cessation
- 1995-04-14 CN CN95193325A patent/CN1059905C/zh not_active Expired - Lifetime
- 1995-04-14 MX MX9604694A patent/MX9604694A/es unknown
- 1995-04-14 EP EP02014322A patent/EP1266899B1/en not_active Expired - Lifetime
- 1995-04-14 BR BR9507323A patent/BR9507323A/pt active IP Right Grant
- 1995-04-14 AT AT02014322T patent/ATE350384T1/de active
- 1995-04-14 EP EP95915671.2A patent/EP0763039B3/en not_active Expired - Lifetime
- 1995-04-14 DE DE122008000023C patent/DE122008000023I1/de active Pending
- 1995-04-14 DE DE69529897.6T patent/DE69529897T3/de not_active Expired - Lifetime
- 1995-04-14 JP JP52710595A patent/JP3725901B2/ja not_active Expired - Lifetime
- 1995-04-14 PL PL95316948A patent/PL183178B1/pl unknown
- 1995-04-14 CZ CZ963052A patent/CZ284567B6/cs not_active IP Right Cessation
- 1995-04-14 DK DK02014322T patent/DK1266899T3/da active
- 1995-04-14 SK SK1330-96A patent/SK281787B6/sk not_active IP Right Cessation
- 1995-04-14 RU RU96122172A patent/RU2134267C1/ru active
- 1995-04-14 DK DK95915671T patent/DK0763039T3/da active
- 1995-04-14 HU HU9602893A patent/HU225915B1/hu active Protection Beyond IP Right Term
- 1995-04-14 SI SI9530648T patent/SI0763039T1/xx unknown
- 1995-04-14 EP EP06026307A patent/EP1760083B1/en not_active Expired - Lifetime
- 1995-04-14 PT PT95915671T patent/PT763039E/pt unknown
- 1995-04-14 DE DE69535363T patent/DE69535363T2/de not_active Expired - Lifetime
- 1995-04-14 AT AT95915671T patent/ATE234307T1/de active
- 1995-04-14 AT AT06026307T patent/ATE537176T1/de active
- 1995-04-14 ES ES06026307T patent/ES2375730T3/es not_active Expired - Lifetime
- 1995-04-14 SI SI9530730T patent/SI1266899T1/sl unknown
- 1995-04-14 WO PCT/US1995/004603 patent/WO1995028406A1/en active IP Right Grant
-
1998
- 1998-11-24 HK HK03101048.7A patent/HK1048816B/zh not_active IP Right Cessation
- 1998-11-24 HK HK98112275A patent/HK1011352A1/xx not_active IP Right Cessation
-
2003
- 2003-05-13 LV LVP-03-47A patent/LV13038B/en unknown
- 2003-09-12 CY CY0300065A patent/CY2378B1/xx unknown
-
2008
- 2008-05-15 LU LU91438C patent/LU91438I2/fr unknown
- 2008-05-15 NL NL300348C patent/NL300348I2/nl unknown
- 2008-05-16 FR FR08C0018C patent/FR08C0018I2/fr active Active
- 2008-05-19 CY CY200800012C patent/CY2008012I2/el unknown
-
2013
- 2013-06-28 US US13/931,400 patent/USRE44768E1/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4650803A (en) * | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
WO1992005179A1 (en) * | 1990-09-19 | 1992-04-02 | American Home Products Corporation | Carboxylic acid esters of rapamycin |
US5233036A (en) * | 1990-10-16 | 1993-08-03 | American Home Products Corporation | Rapamycin alkoxyesters |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103140494A (zh) * | 2010-08-04 | 2013-06-05 | 美利奴生命科学有限公司 | 制备具有抗增殖特性的新的42-o-(杂烷氧基烷基)雷帕霉素化合物的方法 |
CN104086564A (zh) * | 2014-07-30 | 2014-10-08 | 江苏奥赛康药业股份有限公司 | 一种高纯度坦罗莫司的制备方法 |
CN104086564B (zh) * | 2014-07-30 | 2019-02-05 | 江苏奥赛康药业股份有限公司 | 一种高纯度坦罗莫司的制备方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1059905C (zh) | 雷怕霉素羟基酯,它们的制备方法及其药用组合物 | |
CN1085212C (zh) | 雷怕霉素42-肟类化合物和羟胺类化合物 | |
US5489680A (en) | Carbamates of rapamycin | |
US5391730A (en) | Phosphorylcarbamates of rapamycin and oxime derivatives thereof | |
MXPA96004694A (en) | Hydroxysteres of rapamycin, process for supreparation and pharmaceutical compositions that loscontie | |
JPH08503210A (ja) | 免疫抑制剤としてのラパマイシンの炭酸エステル | |
CN1271361A (zh) | 半衰期缩短的包含四唑的雷帕霉素类似物 | |
EP1109789B1 (en) | Triptolide prodrugs having high aqueous solubility | |
CN1132512A (zh) | 环c-22位加以稳定化处理的雷帕霉素衍生物 | |
JPH06293774A (ja) | 大環状免疫調節剤 | |
WO2002028866A2 (en) | Hydroxyesters of 7-desmethylrapamycin | |
JPH08501084A (ja) | 27−ヒドロキシラパマイシンおよびその誘導体 | |
EP0593227B1 (en) | Carbamates of rapamycin | |
US6121257A (en) | Sulfamate containing macrocyclic immunomodulators | |
AU679854C (en) | Rapamycin hydroxyesters, process for their preparation and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: WYETH CORP. Free format text: FORMER NAME OR ADDRESS: AMERICAN HOME PRODUCTS CORP. |
|
CP01 | Change in the name or title of a patent holder |
Patentee after: Wyeth Corp. Patentee before: American Home Products Corp. |
|
C17 | Cessation of patent right | ||
CX01 | Expiry of patent term |
Expiration termination date: 20150414 Granted publication date: 20001227 |